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ABSTRACT 
The development, maintenance and repair of the skeletal system are dependent on 
the differentiation of both chondrocytes and osteoblasts from their common progenitor, 
the mesenchymal stem cell (MSC). The A2B adenosine receptor (A2BAR) is a G-
protein-coupled receptor that signals by increasing cAMP and/or activating 
phospholipase C signaling. Considering the published roles of cAMP on MSC 
differentiation, and our finding that the expression of the A2BAR is induced following 
injury, we hypothesized that ablation or activation of the A2BAR impacts the 
differentiation of osteoblasts and chondrocytes and that this would manifest as changes in 
skeletal development and bone fracture repair. Activation of the A2BAR increased the 
differentiation of bone marrow-derived MSCs to osteoblasts by increasing mRNA 
expression of the transcription factors runt-related transcription factor 2 (Runx2) and Sp7 
transcription factor (Osterix), which are essential for osteoblast differentiation. To 
examine the effect of the A2BAR on bone formation in vivo, we subjected wild type 
IV 
(WT) and A2BAR knockout (KO) mice to bone fracture. A2BAR KO mice had impaired 
bone formation during fracture repair with increased cartilage volume. As fracture repair 
recapitulates the events that occur during endochondral ossification, we compared the 
growth plates of WT and A2BAR KO mice. In comparison to WT, A2BAR KO mice 
had a shorter growth plate initially, but a taller growth plate at a later age. These results 
suggest that initiation of endochondral ossification may be delayed in the A2BAR KO 
mice. Finally, we investigated whether the A2BAR is involved in chondrocyte 
differentiation. A2BAR activation decreased mRNA expression of the key transcription 
factor for chondrocyte differentiation, SRY (sex-determining region Y)-box 9 (Sox9) and 
decreased the mRNA expression of the hypertrophic chondrocyte marker Collagen X. 
Taken together, these data demonstrate a previously unidentified role of the A2BAR 
receptor in regulating MSC differentiation to both osteoblast and chondrocyte lineages. 
Further, we showed that mice null for the A2BAR have dysregulated bone formation 
during development and after injury. The importance of this receptor during bone 
formation and fracture repair could have implications for A2BAR-based therapies for 
bone maintenance and repair . 
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CHAPTER I. INTRODUCTION 
The development of the skeletal system, as well as its repair, are dependent on the 
differentiation of both chondrocytes and osteoblasts from their common progenitor, the 
mesenchymal stem cell (MSC). There are two processes from which bone is formed. 
During intramembranous osteogenesis, bone is formed directly from MSC differentiation 
to osteoblasts. This process gives rise to flat bones, such as those of the skull and 
clavicle. In contrast, endochondral osteogensis requires MSC differentiation to 
chondrocytes and the formation of a cartilage template, which is followed by ossification 
by osteoblasts. This process is responsible for the formation of the long bones of the 
skeleton, and remains active in the growth plates of growing bones (reviewed in[l, 2]). 
Bone fracture repair recapitulates the events of skeletogenesis and is, therefore, used as 
an experimental model of bone formation [3]. These processes are regulated by paracrine 
actions between osteoblasts and chondrocytes and, thus, proper skeletogenesis requires 
precise control over the differential differentiation of the MSC to these lineages. Failure 
of chondrocyte or osteoblast precursors to proliferate and differentiate leads to various 
types of skeletal dysplasias, depending on the pathway involved (reviewed in [4]). 
Skelatogenesis: an overview 
The osteochondroprogenitor 
The majority of what is known about MSC differentiation along the skeletal 
lineage comes from embryology. Endochondral and intramembranous skeletogenesis 
begins with the proliferation and migration of mesenchymal cells to form condensations. 
These condensations are characterized as tightly packed cells that express specific 
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condensation markers, and will determine the position, shape and size of the skeletal 
elements [5]. The transforming growth factor-~ (fGF~) and Hox family of molecules, 
derived from the epithelium, have been implicated in directing the formation of 
condensations. These molecules, along with the cell-cell and cell-matrix interactions that 
result from the compact nature of these cells, are thought to trigger MSC differentiation 
[5, 6]. 
As the osteochondroprogenitor is multipotent, lineage fate decisions must be 
made and maintained. The transcription factor runt-related transcription factor 2 (Runx2) 
is believed to determine osteoblast versus chondrocyte differentiation. Various studies 
have shown that upregulation of Runx2 induces osteoblastic differentiation, while it's 
persistent expression in chondrocytes causes premature maturation and mineralization 
[7]. Runx2 is expressed in prechondrogenic and preosteogenic condensations, but during 
early embryogenesis, outside signals regulate its expression [5]. Homeobox protein A2 
(Hoxa-2) and Wnt (wingless-type MMTV integration site) signaling have both been 
implicated in this process. Through specific inactivation in the developing limbs of mice, 
~-catenin, a downstream effector protein of Wnt signaling, was found to be essential to 
bone development as these embryos had impaired osteoblast differentiation [8]. Also, it 
was found that if ~-catenin is activated, it upregulates Runx2 expression and MSCs 
differentiate to osteoblasts, rather than chondrocytes [8-10]. These results implicate ~­
catenin in the deterrninantation of osteo- versus chondrogenesis. 
Chondrogenesis 
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Chondrocytes are the first skeletal cells to arise, and their differentiation depends 
on the expression of the transcription factor sry (sex determining region Y)-box 9 (Sox9). 
The importance of Sox9 was discovered when a genetic mutation in humans was found to 
be the cause of campomelic dysplasia, characterized by severe cartilage abnormalities 
[11, 12]. Genetic deletion of Sox9 in mice blocks chondrocyte differentiation at the point 
of mesenchyme condensation, indicating that it is necessary for the induction of 
chondrocyte differentiation [13]. In the prechondrogenic mesenchyme, Runx2 IS 
expressed along with Sox9 [14]. However studies show Sox9 to be dominant over Runx2 
[15] by promoting Runx2 protein degradation as well as inhibiting its transcriptional 
activity [16]. Additionally, Nkx3.2 inhibits Runx2 transcription, enforcing the 
differentiation to chondrocytes [17]. Sox9, along with co-activators Sox5 and Sox6, binds 
and activates promoters of chondrocyte specific genes. These include collagen 2a1 
(Col2a1) and aggrecan [5]. 
Also important to chondrogenesis is chondrocyte maturation. This involves the 
transition of chondrocytes from proliferating, to non-proliferating and hypertrophic, and 
eventually apoptotic [2]. The expression of Sox9, along with the activation of cAMP 
response element binding protein (CREB) and c-Fos, maintains the chondrocytes in a 
proliferative state [2]. In order for the chondrocytes to exit the cell cycle and become 
hypertrophic, Runx2 must be upregulated and Sox9 suppressed. The exit from the cell 
cycle and apoptosis is necessary for the eventual invasion by osteoblasts and ossification 
of the bone matrix [2]. 
Osteoblastogenesis 
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The transcription factor Runx2 is absolutely necessary for osteoblast 
differentiation. Runx2 knockout (KO) mice show a total absence of differentiated 
osteoblasts and, therefore, lack any bone [I8, I9]. As Sox9 suppresses Runx2 activity, 
osteoblast differentiation occurs when Runx2 is upregulated and stabilized. Twist 
proteins, transcription factors with important roles in embryogenesis, also negatively 
regulate Runx2, by blocking its DNA binding domain and inhibiting its ability to 
upregulate osteoblast specific genes [20]. Therefore, the inhibition of Twist proteins, 
specifically Twist-I and/or Twist-2, is thought to initiate osteoblastogenesis [20]. 
Members of the distal-less (Dix) family of homeobox proteins (Dix5 and Dlx6) are 
important for endochondral ossification in the developing appendicular and axial skeleton 
[2I]. Dlx5 has been shown to act directly upstream of Runx2, by binding its gene 
promoter, [22] and Dlx5/Dix6 double knockout mice exhibit delayed ossification [23]. 
Other homeobox transcription factors are msh homeobox I and 2 (Msxl/Msx2), though 
whether their regulation of osteoblast differentiation is positive or negative is still 
controversial [24]. Msxl/Msx2 may be necessary for the expression of Runx2, as the 
Msxl/Msx2 double KO fails to express Runx2 [25], although more direct evidence is 
needed (Schematic I summarizes major transcriptional regulators of osteoblastogenesis). 
Wnt signaling has also been implicated in triggering osteoblast differentiation (reviewed 
in [26, 27]). There is a ~-catenin responsive TCF/Lef binding site on the Runx2 gene 
promoter, and therefore, may upregulate Runx2 expression [28]. Once upregulated, 
Runx2 triggers osteoblast differentiation and bone development by binding promoters of 
osteoblast specific genes, including Osterix, alkaline phosphatase and Osteocalcin. Once 
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its expression is stabilized, Runx2 inhibits Sox9 transcriptional activity [29], further 
pushing the MSC to the osteoblast lineage. In addition to regulating osteoblast 
differentiation, Wnt signaling also regulates osteoblast number and function. Post-natal 
deletion of P-catenin in Osterix-expressing cells causes osteopenia, however the number 
of osteoblasts is increased [30]. Therefore a continued investigation of the role of Wnt 
signaling in osteoblast function, particularly osteoclast regulation, is needed. 
In summary, it appears that the differentiation to chondrocytes may occur by 
default, when Runx2 and osteoblast differentiation are suppressed. It is also possible that 
signals that upregulate Sox9 are responsible for the suppression of the osteoblast 
differentiation program. Schematic 2 illustrates these two paths of differentiation. 
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Schematic 1: Transcriptional regulators of MSC differentiation to skeletal lineages. 
Osteochondroprogenitors arise from MSCs and express both Runx2 and Sox9. Multiple 
transcriptional regulators (including Dlx5, Nkx3.2 and Msxl/Msx2) have been found to 
modify the expression of Runx2 and Sox9 and, therefore, drive differentiation to 
chondrocytes or osteoblasts. 
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Schematic 1 
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Schematic 2: Osteoblast versus chondrocyte differentiation. Differentiation to the 
chondrocyte lineage may occur, by default, with suppression of Runx2 and 
osteoblastogenesis. Conversely, osteoblast differentiation may be actively suppressed by 
Sox9 and/or its regulators. 
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Cyclic-AMP as a regulator of osteoblastogenesis and chondrogenesis 
Though there are master regulators that direct MSC differentiation, various other 
molecules have been demonstrated to modulate the process. Here, we will focus on those 
that signal through cyclic-AMP (cAMP). cAMP is a ubiquitous second messenger that is 
synthesized from ATP by adenylyl cyclases. cAMP levels are regulated by different 
stimuli, one major effector being G-protein-coupled receptors. These receptors are 
classified either as stimulatory (Gas) or inhibitory (Gai) of adenylyl cyclase. Changing 
levels of cAMP is translated to the cell through cAMP's action on cyclic nucleotide-gated 
ion channels, on exchange proteins known as Epacs, and on Protein Kinase A (PKA) 
(reviewed in [31]). PKA activation further perpetuates the signal by phosphorylating 
different target proteins. Ultimately, cellular transcription can be modified through the 
cAMP-dependent transcription factors CREB, CREM and ATF-1 (reviewed in [31-33]). 
Cyclic AMP is degraded by phosphodiesterases, which remove a phosphodiester bond 
and produce AMP. These enzymes play a major role, not only in terminating the signal , 
but also in regulating the amplitude and duration of the signal [34]. 
The role of Gas signaling in osteoblast differentiation was spurred by the finding 
that individuals with mutations in the Gas gene have a bone phenotype. Inactivating 
mutations in the Gas gene (GNAS) cause Albright hereditary osteodystrophy [35], 
whereas activating mutations cause fibrous dysplasia of bone [36]. To explore its role in 
bone development, Hsaio et al., created a mouse expressing an engineered Gas receptor 
in osteoblasts and found it to have highly increased bone mass [37]. Conversely, 
complete knockout of Gas receptors in osteoblasts reduced the number of osteoblasts and 
10 
impaired bone formation [38, 39]. Though interpretation of these types of experiments is 
limited, they support a potential role for cAMP signaling in MSC differentiation. In 
accordance, parathyroid hormone (PTH), a hormone critical for bone development and 
homeostasis, signals through a G-protein-coupled receptor (reviewed in [40]), reinforcing 
the importance of cAMP signaling in skelatogenesis. The PTH receptor binds PTH, as 
well as PTH related protein (PTHrP), and is coupled to Gas as well as Gaq [41]. There is 
a long history of PTH's effect on osteoblast differentiation. Studies in PTH receptor KO 
mice show that the signaling is not required for osteoblast differentiation [42], however 
PTH has been demonstrated to enhance osteoblast differentiation (reviewed in [43]). 
Recently, it was found that PTH interacts with canonical Wnt signaling and FGF-2 
signaling and that this interaction enhances osteoblast differentiation (reviewed in [44]). 
Also, PTH signaling was found to interact with bone morphogenetic protein signaling, 
which additionally enhances osteoblast differentiation [45-48]. 
The direct effect of cAMP on chondrogenesis has not been fully investigated. In 
one study, treatment of rabbit chondrocyte cultures with cAMP analogs was found to 
suppress terminal differentiation and hypertrophy of chondrocytes. Similarly to 
osteoblasts, PTH is not required for chondrocyte differentiation [42]. However, PTH 
treatment of C3H10Tl/2 cells can enhance the early stages of chondrocyte differentiation 
while suppressing chondrocyte maturation [49]. Additionally, limb explants from PTHrP 
KO mice displayed accelerated chondrocyte maturation [50]. 
cAMP effect on transcriptional regulators of osteoblastogenesis 
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Studies have shown that increasing intracellular levels of cAMP in cell lines or in 
primary mouse and human MSCs, through cAMP analogs or forskolin (a direct adenylyl 
cyclase activator), has a positive effect on Runx2 expression [51-54]. In addition , 
activation of receptors that signal through cAMP increases Runx2 expression in MSC cell 
lines and in primary rodent MSCs. These include the PTH receptor [55] and the A2B 
adenosine receptor [54, 56]. This increase in expression may be due to cAMP activation 
of CREB, as the Runx2 promoter contains a functional CREB domain [57]. Another 
likely effect of cAMP is its modulation of Runx2 activity. Runx2 has putative PKA 
phosphorylation sites in its activation domain, and treatment with a PKA-specific cAMP 
analog increases its phosphorylation [58, 59] and activation of the collagenase-3 
promoter [58] and the matrix metalloproteinase-13 promoter [59] . The role that PKA 
phosphorylation of Runx2 has in vivo during osteoblast differentiation remains to be 
determined. 
As mentioned earlier, Osterix is another transcription factor essential for 
osteoblast differentiation and bone development. As Runx2 KO mice do not express 
Osterix [18, 19] but Osterix KO mice do express Runx2, it was deduced that Osterix is 
downstream of Runx2 [60]. Analysis of the Osterix gene promoter identified a Runx2 
binding site, and Runx2 was reported to upregulate Osterix expression [61]. A putative 
CREB site was also found in this gene promoter, suggesting cAMP may be able to 
regulate Osterix expression [61]. In support of this, treatment of cells lines or primary 
mouse MSCs with cAMP analogs increases Osterix expression [51, 54, 62]. However, 
exposure to relatively high cAMP (1 mM) inhibits its expression in UM-106-01 cell line 
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or in mouse primary osteoblasts [63]. Similarly to Runx2 expression, Gas receptor 
activation causes an increase in Osterix expression [54], the mechanism of which remains 
to be demonstrated. 
Dlx5, an upregulator of Runx2 [22], is phosphorylated by PKA, which increases 
Dlx5 protein levels by augmenting its stability. PKA signaling also increases Dlx5 
transcriptional activity. Therefore, PKA signaling enhances Dlx5-induced osteoblast 
differentiation [64]. 
Of note, some have reported a negative effect of cAMP on osteoblast 
differentiation. Yang et al., found that the PKA inhibitor, PKI, increased the expression 
of Runx2 in a human MSC-derived cell line while forskolin, 3-isobutyl-1-methylxantine 
(IBMX) and a cAMP analog decreased the expression of osteopontin [65]. Koh et al., 
found forskolin to decrease Osteocalcin expression in MC3T3-E1 cells. Forskolin also 
decreased the number of mineralized nodules formed by rat primary calvarial cells [66]. 
Tintut et al., reported that treatment of MC3T3-E1 cells with forskolin decreased the 
activity of alkaline phosphatase and inhibited mineralization, as well as decreased the 
expression of alkaline phosphatase, Bone sialoprotein, Osteocalcin and Osteopontin [67]. 
The discrepancy in reported effects of cAMP on osteoblastogenesis may be due, in part, 
to the relatively high concentration of forskolin or cAMP analog used (1 0-100 uM). For 
instance, Turksen et al., found that treatment with 10 f.tM of forskolin inhibited osteoblast 
differentiation while 1 nM increased it [68]. 
cAMP effect on Sox9 and chondrogenesis 
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Multiple studies have suggested synergism between cAMP signaling and Sox9 
expression. The Sox9 promoter contains aCRE site [69] and, using a Sox9 gene promoter 
reporter construct in various MSC cell lines, it was reported that binding of this site by 
CREB increase Sox9 promoter activity [70]. 
Sox9 interacts with CREB binding protein (CBP) and p300 to increase its 
transcriptional activity. Using a Col2a1 gene promoter reporter construct in a 
chondrocyte cell line, as well as a Gal4-Sox9 fusion protein, it was reported that co-
transfection with CBP and/or p300 increased Sox9 activity as a transcriptional activator 
[71]. 
A yeast two-hybrid screen of Sox9 binding partners identified the PKA catalytic 
subunit as interacting with Sox9 [72]. This prompted the investigation of PKA-dependent 
Sox9 phosphorylation and two serine residues were found to be phosphorylated [72]. 
Phosphorylation of these sites by PKA increased Sox9 activation of the Col2a1 gene 
promoter [72]. Zhao et al., investigated this finding further by mutating the serine 
residues. The absence of PKA phosphorylation partially reversed PKA enhancement of 
Sox9 activity, suggesting that PKA augmented Sox9 activity through multiple 
mechanisms. The investigators found an interaction between Sox9 and CBP in 
chondrogenic differentiating C3H10Tl/2 cells by using co-immunoprecipitation, and this 
interaction increased Sox9 transcriptional activity. The importance of this interaction was 
confirmed by mutating a CREB site in the region of the Sox9 interaction, which reversed 
the effect [73]. Therefore, cAMP signaling, by means of PKA, enhances Sox9 expression 
and transcriptional activity through direct phosphorylation and activation of CREB. In 
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addition to findings in a cell line, differentiation of chick limb bud chondrocytes in the 
presence of the PKA inhibitor H89 blocked chondrogenesis. The authors found PKA to 
promote chondrogenesis by down-regulating N-Cadherin through a PKC-dependent 
pathway [74]. 
Taken together, it appears that cAMP signaling is capable of upregulating Runx2, 
a master regulator of osteoblasts, and Sox9, a master regulator of chondrocytes. Since 
Sox9 is an inhibitor of Runx2 expression, it is possible that the sum effect of cAMP on 
lineage determination depends on its concentration, cellular localization and a possible 
regulatory loop. 
Adenosine receptors 
Adenosine is a regulatory metabolite and its receptors are comprised of a family 
of seven transmembrane domain G protein-coupled receptors. Al and A3 adenosine 
receptors (AlAR and A3AR) are coupled to Gai and are, therefore, adenylyl cyclase 
inhibiting, whereas A2A and A2B adenosine receptors (A2AAR and A2BAR) are 
coupled to Gas, which stimulates adenylyl cyclase and produces a cAMP signal. The 
A2BAR may also be coupled to Gaq, which activates phospholipase C [75]. A2BAR has 
a relatively low affinity for adenosine. High extracellular concentrations of adenosine can 
be achieved during cell injury or stress [76] . A2AAR and A2BARs are widely expressed 
to varying degrees, with high expression in the vasculature [77]. Our laboratory and 
others have shown that A2BAR expression is inducible under stress conditions such as 
inflammation and hypoxia (reviewed in [78]). A2AAR and A2BAR are expressed in 
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MSCs [56, 79], and interestingly, high expression of the A2AAR and A2BAR receptors 
can be found in cartilage [80]. 
Adenosine receptors and osteoblast and chondrocyte differentiation 
Only recently has the role of adenosine receptors in osteoblast differentiation been 
examined . In a broad sense, purinergic signaling was looked at in the context of bone , 
and ATP receptors (P2X and P2Y) were found to promote differentiation and 
proliferation in an osteoblast cell line (MC3T3-E1) [81]. It was found that after bone 
injury and when exposed to hypoxic conditions, rat osteoblasts secrete ATP in the high 
nM to f..tM range [82] . This extracellular ATP is available for catabolism to adenosine by 
ectonucleotidases , which are expressed on osteoblasts [79]. In accordance , it was recently 
demonstrated that genetic ablation of the ectonucleotidase CD73 results in osteopenia and 
decreased osteoblast differentiation in mice [83]. 
In vitro studies found adenosine receptors to be expressed in both human [79] and 
rodent MSCs [56]. Based on its expression and measurements of cAMP levels after 
agonist treatments of rat MSCs, Gharibi et al., concluded that the A2BAR is the dominant 
receptor, relative to other adenosine receptors , and that its expression increases during 
osteoblast differentiation [56]. In human MSCs, A2BAR activation increased osteoblast 
differentiation , as determined by an increase in alkaline phosphatase activity [79]. 
Similarly, in rat MSCs, activation of the A2BAR increased Runx2 and alkaline 
phosphatase expression, as well as the number of mineralized nodules [56]. We found 
bone marrow-derived MSCs from A2BAR KO mice to have decreased osteoblast 
differentiating potential , with diminished expression of Runx2 and Osterix . Activation of 
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the A2BAR with pharmacological agonists increased the expression of these transcription 
factors, as well as caused an increase in the number of mineralized nodules. Treatment 
with a cAMP analog also increased the expression of Osterix, suggesting cAMP may be 
the mechanism of action for A2BAR effect on differentiation. Additionally, the A2BAR 
KO mouse had mild osteopenia, and a delayed or impaired bone fracture healing response 
[54]. 
There have been few reports on the effect of the cAMP inhibitory adenosine 
receptors, AlAR and A3AR on osteoblast differentiation. Overexpression of the AlAR 
in an osteoblast precursor cell line led to inhibition of osteoblast differentiation, and 
instead promoted differentiation to adipocytes [84]. However, treatment of human MSCs 
with the AlAR agonist, N6-cyclopentyladenosine (CPA), caused an . . mcrease m 
osteoblast differentiation [79] . In rat MSCs, very little A3AR was found [56] and in 
human MSCs, treatment with the A3AR agonist, 1-Deoxy-1-[6-[[(3-
iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-(3-D-ribofuranuronamide (IB-
MECA), had no effect on osteoblast differentiation [79]. 
A role for adenosine receptors in chondrocyte differentiation has not yet been 
examined and/or reported. However, as Al and A2-type ARs are known to be expressed 
in MSCs [56, 79], and given the published influence of cAMP on Sox9 (as described 
above), it is likely that a role for these receptors on the differentiation of this lineage will 
be found. 
Inflammation and osteoblast and chondrocyte differentiation: implication for 
adenosine receptors 
17 
Inflammation plays a significant role in bone development (reviewed in [85]) and 
regeneration (reviewed in [86]). While adenosine receptor signaling through cAMP has 
the potential to directly influence osteo- or chondrogenesis, cAMP signaling through 
these receptors can also affect the level of inflammatory cytokines systemically or at the 
cellular level (reviewed in [87]). Here, we will focus on a brief survey of the effects of 
inflammatory processes on bone cell differentiation, followed by a summary of A2-type 
adenosine receptors effects on inflammation and its potential influence on bone cell 
lineages. 
The effect of inflammation on osteoblast differentiation 
The effect of inflammation on the skeletal system, including osteoblast 
differentiation, has been well studied , particularly the effects of tumor necrosis factor-a 
(TNF-a) (reviewed in [88]). Experiments by Gilbert et al., in both fetal calvarial cells and 
the osteoblast precursor cell line MC3T3-El show that TNF-a inhibits osteoblast 
differentiation, specifically at the early stage of lineage commitment [89]. Further 
experimentation showed this inhibition to be associated with downregulation of Runx2 
transcription and a subsequent decrease in nuclear Runx2 [90]. Though these authors did 
not find NFKB signaling to be involved , Huang et al., found that inhibition of NFxB 
signaling by overexpression of IKB in ST2 cells, a mesenchymal stem cell line, abolished 
the inhibitory effect of TNF-a on Runx2 gene expression [91]. The inhibitory effect of 
TNF-a on mRNA expression and osteoblast differentiation was confirmed in primary 
mouse MSCs. Here, the authors also found interleukin-lf3 (IL-lf3) to have a similar 
effect [92]. 
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These studies on mRNA expression were complimented by Kaneiki et al., who 
found TNF-a to promote Runx2 protein degradation in C2C12 and 2T3 osteoblast 
precursor cells by upregulating the E3 ligases Smurfl and Smurf2 [93]. In order to 
examine this phenomenon in primary MSCs, Zhao et al., isolated an MSC-enriched 
fraction from the bone marrow of TNF-a overexpressing mice. In these cells they found 
upregulation of the E3 ligase Wwpl relative to cells from WT mice. Further 
experimentation found Wwpl to be upregulated by TNFa and responsible for inhibiting 
osteoblast differentiation. However, in these primary cells, the inhibition was caused by 
the degradation of JunB, a promoter of osteoblast differentiation, rather than affecting 
Runx2 directly [94]. 
In addition to their studies on Runx2, Lu et al., found TNF-a treatment to inhibit 
Osterix mRNA expression, and claim this to be a direct effect of TNF-a signaling 
through MEK and inhibition of the Osterix gene promoter [95]. Additionally they found 
TNF-a-stimulated binding of paired mesoderm homeobox protein l(Prxl), causing 
inhibition of Osterix gene promoter activity and transcription in MC3T3 and C3H10Tl/2 
cells [96]. Interestingly, Prxl is a developmental regulator of skeletogenesis that was 
previously thought to be silenced after embryogenesis [96]. 
Other regulators of osteoblast differentiation are affected by TNF-a. In culture, 
Msx2 has been shown to inhibit osteoblast differentiation [97]. Treatment of C2C12 or 
fetal calvarial cells with TNF-a caused increased expression of Msx2 and reduced 
expression of alkaline phosphatase. This effect was independent of Runx2, as the 
phenomenon was maintained in Runx2 null cells, and overexpression of dominant 
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negative IKB showed NFKB signaling to be involved. To model inflammation induced by 
wear of artificial limbs, macrophages were activated with titanium particles and their 
media, enriched in inflammatory cytokines, was used to treat MC3T3-El cells. Treatment 
with this conditioned media or TNF-a inhibited Runx2 expression and osteoblast 
differentiation and this was attributed to NFKB activation and increased expression of 
sclerostin, an inhibitor of the Wnt pathway [98]. 
The effect of inflammation on chondrocyte differentiation 
Relative to osteoblastogenesis , little is known about the effect of inflammation on 
chondrocyte differentiation. IL-l and TNF-a decreased Sox9 mRNA and protein 
expression in a chondrocytic cell line , MC615, and in primary mouse chondrocytes 
through the NFkB signaling pathway [99, 1 00]. However, in these studies differentiation 
was not directly addressed. To study chondrocyte differentiation , Nakajima et al., 
differentiated a chondrocyte progenitor cell line, ATDC5, in the presence of IL-6. IL-6 
decreased collagen 2al and collagen 10 mRNA expression in a dose-dependent manner 
and inhibited the formation of cartilage nodules [101]. Wehling et al., differentiated 
human MSCs to chondrocytes in the presence of either IL-l or TNF-a. They found that 
both cytokines decreased the size of the cartilage pellet and lowered the amount of 
glycosaminoglycan accumulated. IL-l treatment decreased the expression of Col2al and 
aggrecan mRNA [102]. 
Taken together, it is then quite possible that adenosine receptor modulation of 
inflammatory cytokines affect directly or indirectly the process of MSC differentiation 
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into bone cell lineages. Schematic 3 illustrates a proposed mechanism of A2BAR effects 
on osteoblast differentiation involving CREB and/or TNF-a . 
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Schematic 3: Proposed mechanism for A2BAR action on osteoblast differentiation. 
Activation of the MSC A2BAR triggers cAMP signaling, which may modulate the 
expression and/or activity of a key osteoblast transcription factor, Runx2, and promote 
osteoblast differentiation. A2BAR activation also decreases TNF-a levels, which have an 
inhibitory effect on osteoblast differentiation. 
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Schematic 3 
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Adenosine receptors and inflammation 
One of the principal attributes of adenosine and its receptors is its pro- or anti-
inflammatory effects, most of which are mediated via cAMP signaling. Both pro- and 
anti-inflammatory effects of the A2BAR have been described, and these depend on the 
cell type and stimulus. Additionally, these effects have been ascribed either protective or 
deleterious roles, depending on the context, e.g., chronic versus acute pathology 
(reviewed in [103]). Complete KO of the A2BAR gene results in a slight systemic 
inflammation , as KO animals have elevated plasma levels of TNF-a at baseline, and 
elevated levels of TNF-a and IL-6 expression in macrophages [104]. These differences in 
cytokine levels are exacerbated upon' stress or injury. Treatment of A2BAR KO mice 
with lipopolysaccharide causes an exceptional increase in TNF-a and IL-6 plasma levels 
and in macrophage expression, relative to WT mice [104]. 
The ability of the A2BAR to dampen inflammation in response to a stimuli 
highlights its protective role during stress or injury. The importance of this role is 
confirmed by findings that the expression of the receptor is also induced by these stimuli. 
Treatment of vascular smooth muscle cells with TNF-a causes an upregulation of 
A2BAR expression. Further, this increase was shown to be mediated by NADPH oxidase 
4 (Nox4) signaling [105]. 
As NFKB has an important role in the regulation of cellular inflammation it has 
been a target of investigation in relation to A2BAR signaling . Recently, we found the 
A2BAR to directly bind pl05, an inhibitor of NFKB, stabilizing it and preventing its 
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degradation [1 06]. This mechanism he Ips explain the inflammatory phenotype in the 
A2BAR KO mice and the ability of the A2BAR to down-regulate inflammation. 
Considering the above described effects of TNF-a, IL-l and IL-6 on bone cell 
differentiation, it is possible that some of the A2BAR's recently described protective 
effect in a mouse bone injury model [54] is related to changes in cytokine levels. 
Adenosine receptors as therapeutics for osteoporosis, skeletal injury and arthritis 
A role for adenosine receptors in osteoporosis is gaining increasing momentum. 
In mouse bone marrow-derived cells, antagonism of the AlAR with 8-cyclopentyl-1 ,3-
dipropylxanthine (DPCPX) inhibited the differentiation of osteoclasts (bone reabsorbing 
cells) [107]. Also in these cells, treatment with an A2AAR agonist, 4-[2-[[6-Amino-9-(N-
ethyi-~-D-ribofuranuronamidosyl)-9H-purin-2-yl]amino]ethyl]benzene propanoic acid 
hydrochloride (CGS21680), inhibited the differentiation of osteoclasts, as well as 
inhibited their activity. Additionally, the A2AAR KO mouse has an increased number of 
osteoclasts, as well as reduced bone volume [108]. Similarly, A2BAR KO mice display a 
mild reduction in bone density [54]. In our study , we also found that A2BAR KO mice 
have changes in bone fracture healing with decreased callus bone formation and an 
apparent delay in healing [54]. Though the anti-inflammatory effects of adenosine likely 
have an important role in improving skeletal injury repair , we contend that adenosine, 
through the A2BAR, may also improve healing by promoting osteoblast differentiation 
[54]. Therefore, agonism of the A2-type ARs may be useful as a therapeutic for 
osteoporosis and bone injury. 
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As caffeine is an antagonist of adenosine receptors, its effects on bone may be 
relevant here. In epidemiological studies of risk factors for osteoporosis in humans, 
caffeine was either found to be negatively associated with [109, 110] or not associated 
with bone mineral density [111-114]. It is possible that effects of caffeine are confounded 
by factors such as age, estrogen levels and calcium intake. In a study of over 3,000 
individuals using the Framingham Cohort, it was found that caffeine intake was 
associated with a higher relative risk of hip fracture [115]. In experimental animals, 
caffeine has been shown to inhibit bone formation. When demineralized bone particles 
were implanted subcutaneously, rats that were treated with caffeine had decreased 
chondrogenesis and decreased mineralization [116], suggesting that caffeine impairs new 
endochondral bone formation by inhibiting the proliferation and differentiation of 
chondroprogenitor cells. In addition, chick osteoblasts treated with caffeine had 
decreased collagen expression and alkaline phosphatase activity, resulting in reduced 
matrix formation [117]. Finally, differentiation of osteoclasts from mouse bone marrow-
derived cells was enhanced with caffeine treatment [118]. Whether any or all of these 
negative effects of caffeine on bone formation and maintenance is solely due to 
antagonism of adenosine receptors has not been determined . 
Adenosine receptors have been found to be protective against a variety of 
injuries, including but not limited to cardiovascular (reviewed in [119]), kidney 
(reviewed in [120]), lung (reviewed in [121]), and gastrointestinal (reviewed in [122]). 
As arthritis is an inflammatory disease of the joints, adenosine receptors have been 
investigated in the context of this disease. Direct infusion of adenosine into the joint in a 
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rat arthritis model reduced the pathogenesis of the disease [123]. Methotrexate is a drug 
commonly used for the treatment of rheumatoid arthritis and ameliorates the condition by 
decreasing the inflammatory response in the joints. At least part of its inflammatory 
action is attributed to its ability to increase adenosine release in the joints [124]. 
Currently, the principal receptor to be implicated is the A3AR. An A3AR receptor 
agoinist , CF-101, has been undergoing clinical trials for the treatment of rheumatoid 
arthritis , however the improvement in rheumatoid arthritis has not yet reached statistical 
significance [125]. 
Conclusions 
There are a multitude of signaling molecules and pathways that converge during 
chondrocyte and osteoblast differentiation. The coordination of the spatial and temporal 
pattern of these molecules is necessary for correct bone formation. Through exploration 
of the downstream signaling of G-protein-coupled receptors, cAMP was found to be an 
important component of the signaling pathways needed for full differentiation of MSCs 
along the skeletal lineage. Continued investigation into the contribution of these 
receptors , adenosine receptors among them, to bone homeostasis and regeneration could 
lead to important discoveries with clinically therapeutic implications. 
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Hypothesis of Thesis Research 
Considering the published roles of cAMP on mesenchymal stem cell 
differentiation, and our finding that the expression of the cAMP-elevating A2BAR is 
induced following injury, we hypothesized that ablation or activation of the A2BAR 
impacts the differentiation of osteoblasts and chondrocytes and that this could manifest as 
changes in endochondral ossification during development of the growth plate and during 
bone fracture repair . 
Specific Aims of Research 
1. To examine the role of the A2BAR in bone repair and in the differentiation of 
bone marrow mesenchymal stem cells to osteoblasts; 
2. To examine the impact of A2BAR deletion on skeletal development; 
3. To determine how the A2BAR affects the differentiation of mouse embryonic 
fibroblasts to chondrocytes 
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CHAPTER II. MATERIALS AND METHODS 
Animals and experimental setup 
All procedures were performed according to the Guidelines for Care and Use of 
Laboratory Animals published by the National Institutes of Health. Throughout these 
studies, all animals received humane care that was in agreement with the guidelines of 
and approved by the Institutional Animal Care and Use Committee of the Boston 
University School of Medicine. A2BAR KO mice were originally generated and bred 
onto C57BL/6J (confirmed by Bax Max) in our laboratory [104]. Age- and sex-matched 
C57BL/6J wild type (WT) mice were used as controls. All bone fracture studies were 
performed on adult males between the ages of 15-18 weeks old and all bone marrow for 
in vitro studies was isolated from 6-7 week old mice. Age and sex selection were based 
on previous data and the time course of fracture healing had been established in this 
fracture model by both histological and selected candidate gene profiling [126, 127]. 
Growth plate analysis was performed on femurs from WT (generated in-house) and 
A2BAR KO male mice at exactly 2, 3 and 4 weeks of age. 
Quantitative micro-computed tomography (micro-CT) 
Bone analysis post-fracture 
Fractured femurs were collected, fixed in 4% formaldehyde for 5 days at 4°C, and then 
stored in phosphate buffered saline (PBS) at 4°C. Scans were performed using a Scanco 
micro-CT 40 system (Scanco Medical, Basserdorf, Switzerland) located in the 
Orthopaedic and Developmental Biomechanics Laboratory at Boston University. Scans 
were performed using a 12-micron voxel size resolution with 200 ms integration time, 
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under conditions of 55 E(KVp) and 145 I(~). Reference lines were manually adjusted 
on each individual bone to include the entire callus area. Transverse images scanned by 
the micro-CT were then traced manually with a computer program and stacked to render 
a 3-D image of the callus. 
Subsequent analysis of the scans was carried out using the software program supplied by 
the manufacturer of the micro-CT instrument. Measurements of callus density (volume 
fraction and mineral density) were made directly from the micro-CT image data of each 
specimen. For these measurements, the callus (including the portion of the callus in the 
medullary canal) was first isolated using a semi-automated segmentation procedure that 
excludes the original cortex. A global threshold algorithm was then used which applies a 
fixed, constant threshold to all specimens. A constrained 3-D Gaussian filter (filter width 
= 0.8, filter support = 1 voxel) was used to partially suppress image noise. The total 
callus volume, length, mineralized volume fraction, and mineral density were then 
calculated using standard algorithms provided by the system manufacturer. The mineral 
density was calculated with the aid of a standard curve obtained from weekly scans of a 
set of hydroxyapatite phantoms of five different mineral densities. The mediolateral and 
anteroposterior callus diameters are calculated as the maximum width of the callus in 
each of the frontal and sagittal planes along the length of the callus. 
Bone analysis at baseline 
Cortical and trabecular bone of WT (bred in-house) and A2BAR KO mice were analyzed 
at 4, 8 and 15 weeks of age. Bones were fixed in 4% formaldehyde for 5 days at 4°C, and 
then stored in PBS at 4°C. Scans were performed using a 12-micron voxel size resolution 
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with 200 ms integration time, under conditions of 55 E(KVp) and 145 1(~). For cortical 
bone analysis, the mid-diaphyseal region was found by measuring the total length of the 
bone and dividing in half. From that mid-point, 27 slices (at 12 fA.m/slice) were taken 
above and below, for a total of 54 slices and a scanned region of 0.648 mm. The cortical 
bone was isolated using a semi-automated segmentation protocol with a fixed threshold 
of 263. The total bone volume, cortical bone volume, cortical thickness, average mineral 
density and minimum and maximum cross-sectional area were calculated using standard 
algorithms provided by the system manufacturer. For trabecular bone analysis the 
metaphysis was identified by starting the scans 4.162 mm from the distal end of the bone 
and taking 134 slices (at 12 fA.m per slice) distally for a totaled scanned region of 1.6 mm. 
The trabecular bone was isolated using a semi-automated segmentation protocol with a 
fixed threshold of 263. The total volume, bone volume, trabecular number, trabecular 
thickness and trabecular spacing were calculated using standard algorithms provided by 
the system manufacturer. 
Cartilage analysis 
Femurs from WT (bred in-house) and A2BAR KO mice were collected at 2 and 3 weeks 
of age, wrapped in PBS-soaked gauze and frozen -20°C. Bones were further processed by 
the lab of Dr. Mark Grinstaff at Boston University's Department of Biomedical 
Engineering as described previously [128]. Briefly, the distal femur was scanned by 
micro-CT, incubated for 1 hour at room temperature in CA4+ contrast agent and re-
scanned. Baseline and stained images were subtracted to yield total cartilage. 
The mouse femoral fracture model 
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A closed mid-diaphyseal fracture of the left femur was generated by controlled blunt 
trauma using a scaled-down modification of the apparatus described by Bonnarens and 
Einhorn [129]. Mice were anesthetized via isoflurane and a medial parapatellar skin 
incision was made in the right leg, followed by a medial parapatellar· incision into the 
quadriceps to the patellar ligament insertion, preserving the patellar ligament intact. An 
intramedullary pin entry point was created in the femur using a 25G needle. Then, an 
intramedullary pin (the guide pin of a 25G spinal needle (Becton Dickson, cat. #405181). 
The pin was cut and the patellar ligament was returned to the original position. The skin 
was closed with 5.0 nylon suture (Ethicon, cat. # 698G). A subcutaneous dose of 
0.5mg/kg buprenorphine hydrochloride (American Regent, Inc. NCD 0517-0725-05) and 
0.1mg/kg penicillin (Butler, cat. #035001) was given to each mouse. For enrollment in 
our studies, the location and quality of fractures were assessed immediately after the 
fractures had been generated, while animals were still anesthetized, by X-ray analysis. A 
fracture whose configuration was inconsistent with our standardized placement criteria 
was not used in our studies. Mice were monitored and checked daily for well-being. 
Specimen harvesting and histology 
Femurs were fixed in 4% formaldehyde (1-5 days depending on age of bone) at 4°C, then 
decalcified in 14% w/v EDTA dissolved in water for 5 days at 4°C, then sent to Boston 
University's Experimental Pathology Laboratory Services Core (Cheryl Spencer 
http://www .bumc.bu.edu/eplsc/) for embedding in paraffin and sectioning (5 urn 
sections). 
Safranin 0 and Fast Green 
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Slides were deparaffinized and rehydrated as follows: xylene for 10 minutes, repeated 3x, 
100% ethanol for 10 minutes, 90% ethanol for 5 minutes, 75% ethanol for 5 minutes and 
water for 5 minutes. The slides were then stained with Fast Green FCF (Sigma, cat. 
#F7258) for 8 minutes at room temperature to visualize bone, with Safranin 0 for 10 
minutes at room temperature to visualize cartilage (Sigma, cat. #S8884), and counter-
stained with hematoxylin for 1 minute (Fisher Healthcare, cat. #22-220-109). Slides were 
dehydrated and coversliped with Cytoseal 60 mounting media (Fisher Scientific, cat. 
#NC9527348). Slides were visualized and images were taken using a Nikon Eclipse 50i 
light microscope and a Spot Insight 2 Mega-pixel color camera with Spot version 5.0 
imaging software (Diagnostic Instruments Inc.). 
Tartrate resistant acid phosphatase (TRAP) staining 
Bone sections were deparaffinized, rehydrated (as above) and stained for TRAP positive 
cells using a Leukocyte Acid Phosphatase Kit (Sigma, cat. #386A) according to the 
manufacturers instructions. Slides were then dehydrated and coversliped with Cytoseal 
mounting media. 
Growth vlate analysis 
Growth plate height was measured by analyzing sections of WT and A2BAR KO distal 
femurs stained with Fast Green and Safranin 0. The total height of the growth plate at the 
midline of the bone was measured using NIH software ImageJ (version 1.62; 
http://rsb.info.nih.gov/ij/) and heights were averaged for 4-8 sections per bone. 
Immunohistochemistry 
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Immunohistochemistry for Aggrecan was performed on paraffin sections that were 
deparaffinized and rehydrated (as above). Antigen retrieval was performed by treating the 
sections with a chondroitinase (Sigma, cat. #C2905) solution (0.5 U/ml in 50 mM Tris, 
pH 8.0, 60 mM sodium acetate and 0.02% BSA) at 37°C for 30 minutes. Endogenous 
peroxidase activity was eliminated by treating sections with 3% H20 2 in methanol at 
room temperature for 10 minutes. Sections were blocked in 10% goat serum for 1 hour at 
room temperature. Rabbit anti-mouse Aggrecan antibody (Millipore, cat. #AB1031) was 
added at a 1:50 dilution overnight at 4°C. Goat anti- rabbit HRP secondary antibody 
(Santa Cruz Biotechnology, cat. #SC-2004) was added at a 1:200 dilution at room 
temperature for 1 hour. Staining was visualized using DAB Substrate Kit for Peroxidase 
(Vector Laboratories, cat. #SK-4100) according to the manufacturer's protocol. 
Immunohistochemistry for Collagen type II a1 (Col2al) was performed as for Aggrecan 
with the following changes: antigen retrieval was performed by treating sections with a 
pepsin (Sigma, cat. #P6887) solution (1 mg/ml in 50mM Tris-HCl, pH 2.0) for 10 
minutes at 37°C. Sections were treated with mouse anti- chicken Col2a1 antibody 
(Millipore, cat. # MAB8887) at a 1:50 dilution overnight at 4°C. Goat anti- mouse 
secondary antibody (Santa Cruz Biotechnology, cat. #SC-2005) was added at a 1:200 
dilution at room temperature for 1 hour. Slides were visualized and images were taken 
using a Nikon Eclipse 50i light microscope and a Spot Insight 2 Mega-pixel color camera 
with Spot version 5.0 imaging software (Diagnostic Instruments Inc.). 
Whole skeleton preparation and staining 
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Mice were sacrificed at 1 day of age by isoflurane followed by decapitation and were 
prepared and stained according to a protocol from the lab of Andrew McMahon. Animals 
were skinned and eviscerated and skeletons were fixed in 100% ethanol for 24 hours at 
room temperature, on a rocker. Skeletons were transferred to 100% acetone for 24 hours 
at room temperature, on a rocker. Skeletons were stained with a combination of 1 volume 
of 0.3% alcian blue (in 70% ethanol), 1 volume of 0.1% alizarin red (in 95% ethanol), 1 
volume of glacial acetic acid and 17 volumes of 70% ethanol. Skeletons were stained for 
4 days at 37°C, on a rocker. Excess stain was removed by rinsing skeletons in water, 
followed by incubation in 1% potassium hydroxide [66] for 3 hours at room temperature, 
followed by incubation in fresh 1% potassium hydroxide overnight at room temperature, 
on a rocker. Skeletons were then taken through washes, composed of 20% glycerol/1% 
KOH for 24 hours, 50% glycerol/1% KOH for 24 hours and finally stored in 80% 
glycerol. 
Cells and treatments 
Isolation. culture and osteoblast differentiation of bone marrow-derived mesenchymal 
stem cells (MSCs) 
Mice were euthanized by isoflurane administration, followed by cervical dislocation. 
Femurs and tibiae of mice were dissected and soft tissue removed. Using scissors, the 
ends of each bone were cut enough to reveal the marrow cavity. A 23G needle was 
inserted into the marrow cavity and a 10 ml syringe was used to flush the bones with 
growth media (aMEM supplemented with 10% mesenchymal stem cell qualified fetal 
bovine serum (MSC-FBS; Invitrogen, cat. #12662-029) and 1% penicillin/streptomycin). 
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Cells were plated at 6xl06 cells/ml in growth media and were grown at 37°C with 5% 
C02 • Cells were left undisturbed until day 4 of culture when half of the media was 
removed and replaced. On day 6 of culture all media was removed and cells were treated 
with oseto-inductive reagents (10 nM dexamethasone, 0.04 ~-tM L-ascorbic acid and 8 
mM ~-glycerophosphate, disodium salt), as described by Edgar et al., [130]. Thereafter, 
media was changed every two days and osteo-inductive reagents added. 
Generation and culture ofprimary osteoclasts 
Bone marrow was isolated from mice as described above. Cells were plated at 6xl06 cells 
per ml (day 0). The following day (day 1) non-adherent cells were collected and washed 
1x with PBS. Cells were re-plated at 4x106 cells per ml in media containing 30 ng/ml 
recombinant mouse monocyte-colony stimulating factor (M-CSF, Rand D Systems, cat. 
#416-ML). On day 3, media was replaced with media containing 30 ng/ml M-CSF and 30 
ng/ml recombinant mouse receptor activator of nuclear factor K-B ligand (RANKL, R 
and D Systems, cat. #462-TR). On days 5 and 7, 50% of media was replaced and M-CSF 
and RANKL was added to a final concentration of 30 ng/ml each. On day 8, cells were 
fixed in 0.5% glutaraldehyde and stained for osteoclast marker, using TRAP staining as 
described above. Osteoclasts were additionally identified based on morphology (large 
size and multiple nuclei). 
CJHJOTJ/2 cell culture and differentiation 
C3H10Tl/2 cells were obtained as a gift from Dr. Stephen Farmer, Boston University 
School of Medicine, Department of Biochemistry. Cells were originally obtained from 
ATCC (cat. # CCL-226). Cells were grown in aMEM with 5% FBS (Invitrogen, cat. 
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#10437-028) and 1% penicillin/streptomycin. Chondrocyte differentiation was induced as 
in Denker et al., [131]. 105 cells were plated in a 10 f.tl drop and allowed 1 hour to attach. 
After the incubation, chondro-induction medium was added (aMEM with 10% FBS, 1% 
penicillin/streptomycin and 100 nM recombinant human bone morphogenetic protein-2 
(BMP-2, Sigma, cat. #H4791). Chondro-induction medium was replaced every other day. 
Cultures were maintained for up to 6 days. 
Generation ofmouse embryonic fibroblasts (MEFs) 
Embryos were collected at age e13. Embryos were removed from the uterus and placed in 
PBS on ice. Embryos were cleaned of extra-embryonic tissue and the head and fetal 
livers were removed. Each embryo was minced and placed in 1 ml of 0.25% Trypsin-
EDT A at 37°C for 15 minutes. The solution was pi petted up and down during the 
incubation to dissociate aggregates. 2 ml of MEF growth medium (DMEM with 10% 
FBS and 1% penicillin/streptomycin) was added and pi petted up and down to disperse 
cells. Cells were centrifuged for 5 minutes at 470 x g and the cell pellet was resuspended 
in growth media at 2x105 cells per ml. Cells were frozen as stocks and thawed as follows: 
as follows: 2x106 cells were resuspended in 1 ml of cryopreservation medium (10% 
DMSO and 40% FBS in growth medium) and vials were placed in a cryopreservation 
container and placed at -80°C. After 24 hours, vials were moved to liquid nitrogen. To 
thaw, the frozen vial was placed in a 37°C water bath until contents began to thaw. Then, 
1 ml of growth media was added to the vial and the entire contents transferred to 9 ml of 
growth media. The cells were centrifuged at 270 x gat 4°C for 5 minutes, the supernatant 
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was removed and the cell pellet was resuspended and cells were plated at 2x1<f cells/ml. 
Mouse embryonic fibroblast culture and differentiation into chondrocytes 
WT C57BL/6 MEFs were purchased from GlobalStem (cat. #GSC-6002) and cultured in 
DMEM with 10% MSC-FBS and 1% penicillin/streptomycin. Chondrocyte 
differentiation was performed as described by Saeed et al. , [132]. 105 cells were plated 
(24-well plate) in a 10 f-tl drop and allowed 1 hour to attach. After the incubation, 
chondro-induction medium was added (1:1 DMEM:F12 with 10% MSC-FBS, 1% 
penicillin/streptomycin, 100 nM BMP-2, 10 mM ~-glycerophosphate, disodium salt and 
250 mM L-ascorbic acid). Chondro-induction medium was replaced every other day. 
Assessment of ex vivo mineralization 
To assess mineralized nodules culture plates were washed three times with PBS, and then 
fixed with 10% formaldehyde at room temperature for 10 minutes. Following fixation, 
cells were washed with deionized water and cell layers were covered with alizarin red 
solution (Millipore, cat. #ECM815) and incubated at room temperature for 30 minutes. 
Following staining, cell layers were rinsed with deionized water until washes ran clear. 
Digital photographs of stained cell layers were then taken with a digital camera from a 
fixed distance on a light box for illumination. The stained area per well was quantified 
using a computerized imaging system, Image-Pro Plus 4.1 (Media Cybernetics). For 
mineral analysis, mouse bone marrow cultures were grown in osteo-inductive media for 6 
days. Cultures were washed in PBS then lyophilized and shipped to the Musculoskeletal 
Repair and Regeneration Core Center at the Hospital for Special Surgery, NY for 
analysis. Freshly dried (120°C, 24 h) KBr (200 mg) was mixed with the samples and 
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pellets were made for spectroscopic analysis. For Fourier Transformed Infrared 
Spectroscopy (FT -IR), samples from tissue culture wells were pooled. Specimens were 
scanned in transmittance on a Nicolet 4700 FT -IR spectrometer. Spectra were collected 
from 400-2000 cm-1. Spectra were first baselined and the mineral to matrix ratio was 
determined as the area under the phosphate peak (900-1,200 cm-1) divided by the area 
under the amide I peak (1,585-1,720 cm-1). 
Assessment of in vitro cartilage accumulation 
Cell cultures were washed with PBS and then fixed in 4% glutaraldehyde for 15 minutes 
at room temperature. Cultures were rinsed 2x with O.lN HCI and stained with alcian blue 
solution (1% alcian blue in 0.1N HCI) at room temperature for 30 minutes. Cultures were 
rinsed with O.lN HCl until washes were clear. Cultures were photographed at 1x 
magnification and images were analyzed for mean intensity of stain using NIH software 
ImageJ (version 1.62; http://rsb.info.nih.gov/ij/). A standard minimal threshold was 
determined using negative control cultures stained with alcian blue. 
Pharmacological treatments 
Treatment concurrent with differentiation 
Immediately after chondro-inductive media was added, cells were treated with 1 ~-tM Bay 
60-6583 (provided to Dr. K. Ravid by Bayer HealthCare AG, Wuppertal, Germany), 1 
~-tM Forskolin (Sigma, cat.# F6886) or vehicle {DMSO). Cells were subsequently treated 
at the first media change (day 2 of culture). 
Pharmacological treatment and cAMP measurement 
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Cells were treated with 1 U/ml adenosine deaminase (Roche, cat. #11936921) 20 minutes 
prior to agonist treatment. Cells were treated with 20 f.tM Papavarine hydrochloride (a 
phosphodiesterase inhibitor) (Sigma cat. # P3510) for 10 minutes prior to agonist 
treatment. Cells were treated with 1 f.tM Bay 60-6583, 10 ~-tM 5' -N-ethylcarboxamido 
adenosine (NECA; Sigma, cat. # E2387), 100 f.tM 8-bromo-cAMP (Tocris Bioscience, 
cat. #1140), 1 f.tM Forskolin or vehicle (DMSO) for 10 minutes. Cells were washed 3 
times with ice cold PBS then lysed by adding 120 f.tl of cold 0.1N HCl and scrapping. For 
normalization, an aliquot of the lysate was assayed for total protein using the BioRad 
Protein Assay Kit (Bio-Rad Laboratories, cat. #500-0001). To measure cAMP, the lysates 
were first methylated and analyzed using a Direct cAMP ELISA Kit (Enzo Life Sciences, 
cat. #ADI-900-066) according to the manufacturer's instructions. 
Quantitative reverse transcription-based polymerase chair reaction (RT-PCR) 
Fractured calluses were collected on days 3, 7, 14 and 21 post-injury and were cut at a 
distance of 5 mm on either side of the fracture. For baseline measurements (day 0), 
femurs of WT and A2BAR KO mice were collected and the mid-diaphyseal region was 
dissected out. For other bone analyses, the entire bone was collected. All bone samples 
were snap-frozen in liquid nitrogen and stored at -80°C until they were used for RNA 
isolation. 
For RNA isolation, bones were pulverized in liquid nitrogen using a mortar and pestle 
and added to 600 f.tl of RLT buffer supplied in the RNeasy Mini Kit (Qiagen, cat . 
#74134). This sample was homogenized 2x for 15 seconds each, using a Fisher Scientific 
Power Gen 1000 S1 homogenizer, then placed on ice. Lysates were placed on a rocker at 
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4°C for 30 minutes, and then centrifuged for 10 minutes at 16,000 x gat 4°C. Supernatant 
was collected and used immediately for reverse transcription. 
For cell culture, Buffer RLT was added and the cells were scraped. Lysate was collected 
and stored at -80°C. Lysates were homogenized using Qiashredder columns (Qiagen, cat. 
#79654) and RNA was isolated with the RNeasy Mini Kit (Qiagen, cat. #74134). 
RNA was reverse transcribed using the High Capacity eDNA Reverse Transcription Kit 
(Applied Biosystems, cat. #4368814) according to the manufacturer's protocol. Gene 
expression was measured using TaqMan Gene Expression Master Mix (Applied 
Biosystems, cat. #4370048) on an Applied Biosystems 7700 Sequence Detector. The 
following Applied Biosystems Taqman Gene Expression Assays (primer/probe sets) were 
used; I8s rRNA (cat. #4319413E), ~-actin (Mm00607939_si), Runx2 
(Mm00501580_m1), Osterix (Mm00504574_mi), Col2ai (Mm01309565_mi) , 
Aggrecan (Mm00545794_mi), GAPDH (cat. #4352339E), Sox9 Mm00448840_m1), and 
C/ebp-~ (Mm00843434_s1). 
Western blot analysis 
Femurs were snap-frozen in liquid nitrogen at the time of collection and stored at -80°C. 
On the day of Western blot analysis, bones were pulverized in liquid nitrogen using a 
mortar and pestle and added to 600 ~-tl of RIPA buffer (1% NP-40, 0.5% sodium cholate, 
O.I% SDS) supplemented with IX proteinase inhibitor (Roche, cat. #II69749800I) and 
IX phosphatase inhibitor (Roche, cat. #0490683700I). This was homogenized 2x for I5 
seconds each using a Fisher Scientific Power Gen 1000 S I homogenizer, then placed on 
ice. Lysates were placed on a rocker at 4°C for 30 minutes, and then centrifuged for 10 
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minutes at 16,000 x g at 4°C. Supernatant was collected and total protein concentration 
was measured using the BioRad Protein Assay Kit (BioRad Laboratories, cat. #500-
0001). After normalizing protein concentration between samples, protein lysate was 
reduced with 4X SDS loading buffer and resolved by 8%-SDS (Aggrecan; molecular 
weight greater than 250 kD) or 10%-SDS (Sox9; molecular weight of 65 kD) gels. 
Proteins were transferred overnight at 34 Vat 4°C on 0.2 ~-tm PVDF membrane (BioRad 
Laboratories, cat. #162-0177) with transfer buffer (25 mM Tris and 192 mM glycine) 
supplemented with 10% methanol and 0.1% SDS (for Aggrecan) or 20% methanol (for 
Sox9). After transfer, membranes were blocked with 10% milk in 1X PBST (lX PBS and 
0.05% Tween) for 1 hour at room temperature and blotted with primary antibody as 
follows: anti- Aggrecan (Millipore, cat. #AB1031) at 1:1,000 dilution for 1 hour at room 
temperature, anti- Sox9 (Santa Cruz Biotechnology, cat. #SC-20095) at 1:1,000 dilution 
for 1 hour at room temperature, anti- B-actin (Sigma, cat. #A5441) at 1:5,000 dilution for 
1 hour at room temperature. Membranes were washed and incubated with the appropriate 
secondary antibodies: goat anti- rabbit (SantaCruz Biotechnology, cat. #SC-2004) or goat 
anti- mouse (SantaCruz Biotechnology, cat. #SC-2005) at dilutions of 1:10,000, except 
for B-actin (1:100,000) for 1 hour at room temperature. Proteins were visualized with 
Immobilon Western Chemiluminescent horseradish peroxidase (HRP) Substrate 
(Millipore, cat. #WBKLS0500). 
Transfection ofC3HlOT1/2 cells with a RUNX2-responsive promoter 
The following plasmids were obtained as a gift from Dr. Xaralabos Varelas, Department 
of Biochemistry, Boston University School of Medicine: p60SE2-luc, pCMV5-B-gal and 
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flag-Runx2, all of which confer ampicillin resistance. Optimal transfection efficiency of 
C3H10Tl/2 cells was found with transfection of 0.5-1.0 ~-tg of DNA with 1 ~-tl of 
Lipofectamine 2000 transfection reagent (Invitrogen, cat. #11668) per well of a 24-well 
plate. Optimal transfection was assessed by the percentage of ~-galactosidase positive 
cells upon transfection with pCMV5-~-gal (yielding approximately 40% positive cells). 
For concurrent transfection and chondrocyte differentiation, C3H10Tl/2 cells were 
grown in 10 em plates until 95% confluent. Cells were transfected with p60SE2-luc 
reporter and pCMV5-~-gal reporter (2: 1 ratio) and 1 ~-tl Lipofectamine 2000 per 1 f.A.g of 
DNA was used. After 24 hours, cells were trypsinized, replated in micromass cultures 
(105 cells/ 10 f.A.l) and differentiated to chondrocytes (as described above). 48 hours post-
chondro-induction, cell lysates were collected using the Luciferase Assay System with 
Reporter Lysis Buffer (Promega, cat. #E4030) and stored at -80°C for subsequent 
analysis. 
Statistical analysis 
Data are presented as means± standard deviation. Data were analyzed using Student's T-
test at a level of significance of p<0.05. 
Generation of the CD68-A2BAR transgenic mouse 
The CD68-A2BAR transgenic mouse, created by Drs. Milka Koupenova and Alexia 
Eliades, were genotyped and bred under my active participation and guidance. The mice 
were created as follows: Starting with an SM22a-hA2BAR-~-globin construct (created 
by Dr. Zhao in our laboratory), the SM22a promoter was excised with Not! (New 
England Biolabs, cat. #R0189S) and Hindlll (New England Biolabs, cat. #R0104S). The 
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human CD68 promoter was obtained from a pcDNA-CD68-intron-A2AAR vector (gift 
from Dr. Chen, BUSM) by excising the promoter and intron region with Clal (New 
England Biolabs, cat. #R0197S) and BsrGI (New England Biolabs, cat.# R0575S). These 
two regions were ligated and the final construct was verified with Stul (the correct insert: 
2 fragments- 0.7 kb and 8.5 kb; no insert: linearizes the vector- 8.2 kb). The correct 
orientation was verified with Sail and Ncol (correct orientation: 2.6 kb and 6.6 kb). The 
final construct was confirmed by DNA sequencing. 
The CD68-A2BAR construct was purified via electroporation and microinjected into the 
pronuclei of fertilized A2BAR-ApoE double KO mouse oocytes to produce transgenic 
mice on an A2BAR-ApoE double KO background. Transgenic founders were generated 
by the Boston University Transgenic Core Facility. Potential founders were screened for 
the CD68 promoter-hA2BAR sequence by tail DNA isolation and PCR as described 
below. 
DNA isolation and genotyping by PCR 
Mouse tails were cut (approximately 0.1 em) and digested in 300 f-tl of digestion buffer 
(100 mM NaCL, 10 mM Tris pH 7.6, 25 mM EDTA pH 8.0, 0.5% SDS) and 6 f-tl of 10 
mg/ml Proteinase K (American Bioanalytical, cat. #AB00925) at 55°C overnight. 
Samples were centrifuged at 16000 x g at 4°C for 10 minutes and supernatant was 
collected. To the supernatant, 100 f-tl of Protein Precipitation Solution (Qiagen, cat. 
#10455697) was added and left on ice for 5 minutes. Samples were centrifuged at 1600 x 
gat 4°C for 10 minutes and the supernatant was collected. To the supernatant, 300 f-tl of 
100% isopropanol was added and samples were gently mixed. The samples were 
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centrifuged at 16000 x g at 4°C for 10 minutes, the supernatant was discarded and the 
pellet was washed with 300 f-1-l of 70% ethanol. After centrifugation (16,000 x g at 4°C 
for 10 minutes) the supernatant was discarded and the pellet air-dried. The DNA was 
resuspended in 30 f-1-l of H20 and the DNA concentration was measured by 
spectrophotometry. 
To screen for CD68-A2BAR, primers were designed to span the hA2B-f3-globin 
interface. For PCR, 100 ng of DNA was added to 12.5 f-1-l of GoTaq Green Master Mix 
(Promega, cat. #M7123), 9.5 f-1-l H20, 1 f-1-l of 1 f-1-M sense primer 5'-
CCACAAGAAACAAAGAGGACACG-3 ' and 1 f-1-l of 1 uM anti-sense primer 5'-
GGGGAAAGAAAACATCAAGGGTC-3' for 45 cycles at 57°C to generate a fragment 
of 613 nucleotides, as detected by electrophoresis on a 1.5% agarose gel. A2BAR KO 
was similarly confirmed with the sense primer 5'-GGCACCTCTCCCTC-3' and the anti-
sense primer 5'-CAGCCTCTGTTCCACATACACT-3' and ApoE KO was confirmed 
with the pnmers 5' -GCCTAGCCGAGGGAGAGCCG-3', 5'-
TGTGACTTGGGAGCTCTGCAGC-3' and 5' -GCCGCCCCGACTGCATCT -3'. 
Two founder lines (denoted #2 and #3) were identified and bred to homozygocity and 
heterozygocity respectively. Homozygotes and heterozygotes were identified by qPCR 
genotyping as described below. Transgenic mice were then crossed with A2BAR KO 
mice to regain the WT ApoE gene. 
DNA isolation and genotyping by qPCR 
Mouse tails were cut (approximately 0.1 em) and DNA isolated with the DNeasy Blood 
and Tissue Kit (Qiagen, cat. #69504) . DNA concentration was measured by 
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spectrophotometry. For the qPCR reaction, 1 Ill (approximately 100 ng) of DNA was 
added to 10 Ill TaqMan Gene Expression Master Mix (Applied Biosystems, ca. 
t#4369016) , 8 Ill of H20 and 1 Ill of human A2BAR primer/probe Gene Expression 
Assay (Applied Biosystems, Hs00386497 _m1) or genomic A2BAR primer/probe Gene 
Expression Assay (Applied Biosystems, Mm01285229_s1) as an endogenous control, as 
the primers/probe are within exon 2 of the mouse A2BAR gene . Data were analyzed 
using the ~~CT method. Genotype was determined by comparing CT values with those 
of known heterozygotes. 
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CHAPTER III: RESULTS 
Aim 1: The role of the A2BAR in bone repair and in the differentiation of bone 
marrow mesenchymal stem cells to osteoblasts 
Materials in this chapter contain writings and images from the article entitled "A2B 
adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and 
bone formation in vivo" Carroll, S.H., Wigner, N.A., Kulkarni, N., Johnston-Cox, H., 
Gerstenfeld, L.C., and Ravid, K. Journal of Biological Chemistry. 2012, val. 287, pp . 
15718-27. ©The American Society for Biochemistry and Molecular Biology. 
MSC differentiation to osteoblasts is impaired in A2BAR KO mice 
MSCs were prepared from the bone marrow of A2BAR KO mice and age-, sex-
and strain-matched wild type (WT) mice. They were then induced to undergo osteogenic 
differentiation by growing the cultures in standard osteo-inductive media (see methods). 
Cultures from WT and A2BAR KO mice showed no differences in total protein content 
at the time of osteo-induction or at subsequent times days when they were analyzed (Fig. 
1). At 9 and 12 days after osteo-induction, bone marrow from A2BAR KO mice showed 
fewer mineralized nodules, demonstrating a reduction in osteoblast differentiation in the 
absence of the A2BAR (Fig. 2A). Using FT-IR spectroscopic analysis (see methods), we 
validated that the accumulated mineral in both the WT and A2BAR KO cultures had the 
typical characteristics of poorly crystalline hydroxyapatite that is seen in newly formed 
bone tissues (Fig. 3). 
We next examined the expression of the two transcription factors that are central 
to osteoblast differentiation, Runx2 and Osterix. As anticipated in WT cultures, osteo-
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induction significantly increases the expression of Runx2 and Osterix after 24 hours (Fig. 
4). Prior to osteo-induction, cells cultured from A2BAR KO mice have a trend towards 
reduced Runx2 expression and significantly reduced Osterix expression. With osteo-
induction, the increase in the expression of both Runx2 and Osterix was significantly 
decreased in the A2BAR KO bone marrow cultures (Fig. 2B). 
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Figure 1: Bone marrow cells from WT and A2bAR KO mice have similar growth in 
vitro. Cells from WT and A2BAR KO bone marrow cultures were lysed just prior to 
osteo-induction (dO), 24 hours (dl) and 5 days post-osteo-induction and total protein was 
measured by Bradford Assay. At test was performed. N=3 , *p>0.05 
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Figure 2: Genetic ablation of the A2BAR leads to impaired osteoblast 
differentiation. A. Bone marrow cells were collected from WT and A2BAR KO mice 
and cultured in osteo-inductive medium (see methods). Cultures were stained with 
alizarin red 9 and 12 days (d9, dl2) after osteo-induction to visualize mineralized 
nodules. Nodules were counted using ImagePro software. At each time point, A2BAR 
KO samples were compared to WT, set at 100%, N=4, *p<O.Ol. B. Measurement of 
osteoblast differentiation markers, Runx2 and Osterix, before adding the osteo-inductive 
reagents (dO) or 24 hours post-treatment (dl). Expression was measured by qRT-PCR 
and normalized to 18s rRNA. Data is presented relative to WT dO, and a t test was 
applied to each WT and A2BAR KO pair at each time point. N=5, *p<0.05. 
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Figure 3. Bone marrow MSC-derived osteoblasts from WT and A2BAR KO mice 
produce hydroxyapatite in vitro. Representative Fourier Transformed Infrared (FT -IR) 
spectra of cultures 10 days post-osteo-induction. Both WT and A2BAR KO cultures 
showed similar peaks in the mineral region. 
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Figure 4. Osteoblast transcription factors are upregulated upon in vitro osteo-
induction. Runx2 and Osterix expression was measured by qRT-PCR prior to (dO) and 
24 hours post (dl)- addition of osteo-inductive reagents. Expression was normalized to 
18s rRNA. A t test was performed for each gene to show a significant increase in 
expression on dl. N=5 , *p<0.05. 
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A2BAR activation increases osteoblast differentiation 
As ablation of the A2BAR impairs osteoblast differentiation, we next tested whether 
activation of the A2BAR could increase differentiation. We treated bone marrow from 
WT and A2BAR KO mice with NECA, an A2-type receptor agonist, or vehicle., 
concurrently with osteo-induction. After 10 minutes of treatment, NECA significantly 
elevated cAMP levels in the WT cells, relative to treatment with vehicle (Fig SA). NECA 
had no significant effect on cAMP levels in the A2BAR KO cells, indicating that there is 
little contribution of the A2AAR to the overall cellular levels of cAMP, consistent with 
the relatively low expression of the A2AAR in MSCs [56, 133]. To test the effect of 
A2BAR activation on nodule formation, NECA or vehicle was added at the time of 
osteo-induction (dO) and at the second media change (d2). Nodules were counted on day 
6 of osteo-induction. We found that treatment with NECA caused a significant increase in 
the number of mineralized nodules in the WT bone marrow in contrast to the A2BAR KO 
cells. Though treatment of A2BAR KO cells with NECA showed a small and non-
significant increase in the number of nodules (Fig. SB) this is likely due to activation of 
other adenosine receptors after long-term exposure to the ligand. In accordance, NECA 
treatment of WT cells caused a significant increase in the expression of Runx2 and 
Osterix as compared to treatment with vehicle (Fig. SC). There was no effect of NECA 
on Runx2 or Osterix expression in the A2BAR KO cultures (Fig. SC), indicating that the 
influence of NECA on gene transcription is due primarily to activation of the A2BAR 
receptor. Since the A2BAR can signal through activation of adenylyl cyclase and the 
upregulation of cAMP, we predicted that cAMP is at least one of the signals responsible 
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for upregulation of Runx2 and Osterix. Treatment of WT cultures with the cAMP 
analog, 8-br-cAMP, highly increased intracellular cAMP levels (8 fold over vehicle 
treated; data not shown) , and significantly augmented Osterix and tended to augment 
Runx2 expression (Fig. SC). Considering these latter data, we are not ruling out the 
possibility that signaling pathways other than cAMP are needed for full upregulation of 
Runx2, and/or that finer tuning of cAMP levels is important for the control of Runx2 
expression. Whereas treating A2BAR KO cultures with NECA did not upregulate Osterix 
expression, treating these cultures with 8-br-cAMP, and therefore bypassing the receptor 
signaling, did significantly increase Osterix expression (Fig. SC). This supports our 
hypothesis that cAMP signaling upon A2BAR activation is , at least partially, responsible 
for the augmented Osterix expression. 
Of note, despite an increase in Osterix expression after a 24 hour exposure to 8-
br-cAMP (Fig. 5C) , longer treatment (at day 0 and day 2 of osteo-induction) caused a 
significant decrease in nodule formation (Fig. 6A). However, we found that this long 
exposure led to a decrease in total cell number and in total protein within the culture (Fig. 
6B), suggesting that the inhibition in nodule formation is due to a secondary inhibition of 
cell proliferation that masks the effect on Osterix upregulation. These results are in 
agreement with previous studies showing high cAMP levels to inhibit proliferation 
(e.g.,[l34]). 
Taken together , these data show that A2BAR ablation has a profound effect on 
osteoblast differentiation (Fig. 2) , and that A2BAR agonism can modulate osteoblast 
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transcription factor expression, and enhance the number of osteoblasts generated in vitro 
(Fig. 5). 
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Figure 5. Activation of A2BAR increases osteoblast differentiation. A. Bone marrow 
cells from WT and A2BAR KO mice were treated with vehicle (DMSO) or 10 ~-tM 
NECA for 10 minutes. cAMP was measured by ELISA and normalized to total protein. 
N=4, *p<0.05. B. Bone marrow cells from WT and A2BAR KO mice were treated with 
vehicle (DMSO) or 10 ~-tM NECA at the time of osteo-induction and at the next media 
change. Six days after osteo-induction, cultures were stained with alizarin red and 
nodules were counted using ImagePro software (as in Fig. 1). The values for each 
condition were compared to vehicle-treated cells, and each such pair was subjected to a t 
test. N=4, *p<0.05. C. Bone marrow cell cultures from WT and A2BAR KO mice were 
treated with vehicle (DMSO), 10 ~-tM NECA or 100 ~-tM 8-br-cAMP at the time of osteo-
induction. Lower doses of 8-br-cAMP were also attempted, yielding variable results (data 
not shown). RNA was collected after 24 hours. Runx2 and Osterix expression was 
measured by qRT-PCR and normalized to 18S rRNA. N=4, *p<0.05. 
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Figure 6. Treatment with 8-br-cAMP decreases nodule formation and cell number 
in vitro. Cells were treated with vehicle (DMSO) or 100 fA.M 8-br-cAMP at the time of 
osteo-induction and at the next media change. A. Cultures were stained with alizarin red 
six days after osteo-induction to visualize mineralized nodules. Nodules were counted 
using lmagePro software. At each time point, A2BAR KO samples were compared to 
WT, set at 100%, N=4, *p<O.Ol. B. Six days after osteo-induction, cultures were 
trypsinized and cell number counted in duplicate. Cells were lysed and total protein 
measured using a Bradford Assay. N=4, *p<0.05. 
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A2BAR KO mice exhibit impaired bone fracture physiology 
In order to assess the role of A2BAR in a model of skeletal injury response, we 
examined callus formation after fracture. Since fracture healing is dependent on the initial 
MSC differentiation into osteoblasts and chondrocytes [135], we hypothesized that the 
reduced potential of A2BAR KO MSCs to differentiate into osteoblasts would be 
manifested as reduced bone formation after fracture. The progression of tissue formation 
and mineralization within the callus was first quantified using micro-CT imaging. Micro-
CT revealed that fracture calluses of A2BAR KO mice showed a smaller overall total 
volume, as well as a decrease in the ratio of bone volume to total callus volume at 14 and 
21 days post-fracture (Fig. 7A). Analysis of tissue sections supported these findings, 
showing that the A2BAR KO sections had larger areas of cartilage staining that had not 
transitioned into mineralized bone tissue (Fig. 7B ). 
In order to assess the progression of skeletogenic differentiation during fracture 
healing, the fracture callus was dissected and analyzed by qRT-PCR. Consistent with 
prior findings [136] for this injury model, a significant upregulation of Osterix and Runx2 
was observed, both during early periods of MSC differentiation at day 3 post-fracture, 
and later starting on day 7 post-fracture, when mineralized cartilage resorption and 
primary bone formation are initiated in the WT animals. In contrast, the A2BAR KO 
mice show less expression of Runx2 and Osterix mRNA at 3 and 7 days post-fracture, as 
compared to WT (Fig. 7C) . Although the level of expression of these factors equalized in 
the WT and A2BAR KO samples by day 14-post fracture, there was still a difference in 
the ratio of mineralized tissue volume to total callus volume 14 and 21 days post-fracture. 
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Such findings suggest that the A2BAR is involved in aspects of the skeletal repair 
process and its absence leads to delayed progression of bone development during fracture 
repair in the A2BAR KO mice. 
Interestingly, the day 14 post-fracture sections from the A2BAR KO mice are 
dominated by cartilage, compared to WT (Fig. 7B), which is expected to delay normal 
fracture physiology [137]. The increased abundance of cartilage seen in A2BAR KO 
sections was validated by assessing the expression levels of chondrocyte markers, 
collagen type II, alpha 1 (Col2a1) and Aggrecan, which are elevated in the A2BAR KO 
fractures (Fig. 8A). Further analysis with immunohistochemistry verified that the 
increased mRNA expression is translated into greater protein contents, based on the 
increased total amount of Col2a1 and Aggrecan staining in the A2BAR KO as compared 
to WT (Fig. 8B). 
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Figure 7. Analysis of callus formation post-fracture in A2BAR KO mice. A. Micro-
cr analysis of bone volume/total volume (BV /TV) and TV of fracture calluses from WT 
and A2BAR KO mice 14 and 21 days post-fracture. B. Representative sections of the 
fracture callus of WT and A2BAR KO mice at d14 and d21 post-fracture. Sections were 
stained with fast green (which depicts bone), safranin 0 (which depicts cartilage) and 
counter stained with hematoxylin. Composite of 4x magnified images. C. The mid-
diaphyseal region (dO), or the fracture callus (d3, 7, 14 post-fracture) of WT and A2BAR 
KO mice were dissected and qRT -PCR was performed for the osteoblast transcription 
factors Runx2 and Osterix and normalized to 13-actin. Data are presented as fold change 
relative to dO. In examining statistical significance, we focused on WT vs. A2BAR KO in 
each set, using at test. N=3-5, *p<0.05. 
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Figure 8. Analysis of chondrocyte markers in fracture calluses of WT and A2BAR 
KO mice. A. The fracture callus (14 post-fracture) of WT and A2BAR KO mice was 
dissected and qRT -PCR was performed for the chondrocyte markers collagen type II al 
(Col2al) and Aggrecan and normalized to f3-actin. N=5, *p<0.05. B. Representative 
immunohistochemical staining of dl4 fracture calluses for Col2al and Aggrecan. Arrows 
depict staining. 4x magnified composite images (left) and lOx magnified images (right). 
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A2BAR KO mice exhibit an osteopenic phenotype 
As the differentiation of MSCs to osteoblasts and chondrocytes during the 
formation of the fracture callus recapitulates skeletogenesis [127, 138, 139], we explored 
the role of the A2BAR on bone development. There is no difference in body weight 
between 15 week old WT and A2BAR KO mice (Table. 1). Micro-CT analysis of the 
cortical bone of the mid-diaphyseal region of 15 week old femurs shows a statistically 
significant reduction in cortical thickness (Fig. 9A,B), which correlates with a lower bone 
volume relative to total volume (BV /TV), as total volume was not different (Table 1). 
Additionally, these mice display a reduction in tissue mineral density (TMD) (Fig. 9A, 
Table 1). This shows that at 15 weeks of age, A2BAR KO mice display a mild osteopenic 
phenotype. Additionally, femurs of 15-week-old A2BAR KO mice were significantly 
shorter than WT, as measured with calipers (Table 1). Shorter femurs may be the result of 
impaired osteoblast differentiation during development, however, we cannot rule out 
other mechanisms, such as impairment in chondrocyte and/or growth plate development. 
There are no significant differences in the cortical bone between WT and A2BAR 
KO mice at 4 or 8 weeks of age (Table 2). However, at 4 weeks of age, A2BAR KO mice 
have fewer trabeculae, a decrease in trabecular thickness and an increase in trabecular 
spacing, as compared to WT mice (Table 2). Additionally, as in the 15 week-old mice, 
femurs of 4 and 8 week old A2BAR KO mice are somewhat shorter, as compared to WT 
(Table 2). 
Analysis of the growth plates of 4-week-old WT and A2BAR KO mice shows no 
statistically significant difference in the total growth plate thickness, proliferating zone 
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thickness or hypertrophic zone thickness, but A2BAR KO growth plates are slightly 
larger (Fig. 10, Table 3). 
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TABLE 1 
Analysis of WT and A2BAR KO bone growth and homeostasis at 15 weeks of age 
Bones were collected from male age-matched wr and A2BAR KO mice at 15 weeks of age. 
Micro-CT cortical analysis was done on the femur mid-{jiaphysis and trabecular analysis was 
done on the distal metaphysis 
15weeks 
WT A2BARKO n/o-value 
Body Welaht fa) 30.92+/- 1.65 30.42+/- 1.03 5/0.58 
Femur Lenath (mml 16.12+/- 0.14 15.50+/- 0.20* 5/<0.001 
Cortical. Analysis 
Total Volume (TV) (mmA3) 1.32+/- 0.09 1.26+/- 0.02 3/0.30 
Bone Volume (BV) (mmA3l 0.70+/- Q.06 0 .. 64+/- 0.04 3/0.18 
TV/BV 0.54+/- 0.03 0.51+/- 0.03 3/0.23 
Corticat Thickness (mm) 0.25+/- 0.01 0.23+/- 0.01* 3/0 . 01 
Mean Oensitv (ma HA!ccm) 1222.40+/- 23.92 1190. 72+/- 25.78 3/0.19 
Min Cross-sectional area. fmm) 1.17+/- 0.09 1.1 2+/- 0.09 3/0.53 
Max Cross-sectional area (mm) 1.52+/- 0.1 0 1.45+/- 0. 12 3/0.49 
Trabecular Analysis 
Trabecular Number 4.73+/- 0.37 4.45+/- 0.65 3/0.50 
Trabecular Thickness lmml 0.05+1- 0.01 0.05+/- 0.01 3/0.33 
Trabecular Spacing (mml 0.21+/- 0.02 0.23+/- 0.03 3/0.40 
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Figure 9. Effect of the A2BAR on cortical bone parameters. A. Mid-diaphyseal 
cortical bone of 15 week-old Wf and A2BAR KO mice were analyzed by micro-Cf. 
A2BAR KO mice exhibit decreased cortical bone volume (BV) as a percent of total 
volume (TV) of the mid-diaphyseal region analyzed , decreased cortical thickness, and 
decreased cortical tissue mineral density (TMD) (mg hydroxyapatite (HA)/cm3) as 
compared to Wf controls. N=5, *p<0.05. B. Representative micro-Cf images of mid-
diaphyseal cortical bone of Wf and A2BAR KO mice , showing small differences in 
overall shape and size . 
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Figure 10. Representative images of the growth plate of WT and A2BAR KO mice. 
Growth plates of the distal femur of 4-week-old WT and A2BAR KO mice were 
sectioned and stained with fast green (which depicts bone), safranin 0 (which depicts 
cartilage) and counter stained with hematoxylin. 4x and 20x magnifications. 
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TABLE3 
Quantification of the growth plate of WT and A2BAR KO mice. 
Heights of the total g.rowth plate, the proliferating zone and the hypertrophic zone of 4-
week-old WT and A2BAR KO mice were calculated by averaging 20 separate 
measurements within the middle 3/4 of the growth plate. 20 sections per mouse were 
quantified 
WT A2BA8KO n/p-value 
Growth plate height (mm) 330.43+/- 35.84 356.26+/- 24.73 3/0.36 
Proliferating zone heiaht (mm) 158.81+/-12.86 163.95+/- 9.77 3/0.61 
Hypertrophic zone height (mm) 1.23.51+/- 14.84 150.51+/- 32.63 3/0.26 
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Together, our results demonstrate that the A2BAR has an important role in the 
promotion of osteoblast differentiation and bone formation with development and after 
fracture. This role is, at least partially, through the control of the expression of osteoblast 
differentiation transcription factors. 
Aim 2: The impact of A2BAR deletion on skeletal development. 
The A2BAR impacts growth plate dynamics 
We previously found A2BAR KO mice to have slightly shorter femurs and 
significantly less trabecular bone [54]. Therefore, we examined the growth plate of these 
mice. Femurs of 1, 2 and 4 week old mice were sectioned and stained with safranin 0 and 
fast green, indicative of cartilage and bone, respectively. Histology of the distal growth 
plate of the femur showed that the growth plate height at 1 week of age is similar in WT 
and A2BAR KO mice (Fig. 11A; N=2). At 2 weeks of age, A2BAR KO mice have a 
significantly shorter growth plate, relative to WT (Fig. 11B). However, at 4 weeks of age, 
the growth plate of A2BAR KO mice is taller relative to WT (Fig. llB). To determine 
whether the resting and proliferating chondrocytes or the hypertrophic chondrocytes were 
accounting for the changes in height, each zone height was measured and normalized to 
total growth plate height. We found no difference in the resting and proliferating zone or 
hypertrophic zone between A2BAR KO and WT bones (Fig. 11C). These results suggest 
that the rates of growth plate development and/or maturation are altered in the A2BAR 
KO mice but that this alteration is not due to changes in one of the zones of the growth 
plate. 
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To examine how potential differences in . chondrocyte differentiation and 
maturation may be contributing to the altered growth plates of A2BAR KO mice we 
measured Sox9, Collagen II type a1 (Col 2a1), Aggrecan and Collagen X type a1 (Col 
10a1) mRNA expression in entire femurs at 2 weeks of age. We chose to utilize the entire 
femur rather than the growth plate so as not to introduce variability in sample collection. 
At 2 weeks of age there tended to be a decrease in Sox9 expression (p=0.07), as well as a 
tendency towards decreased Col 2a1, Col 10a1 and Aggrecan expression in the A2BAR 
KO (Fig. 12). It is possible that significance would be reached with a larger sample size, 
as there is a considerable amount of variability within different biological samples . Sox9 
is a transcription factor expressed early in chondrocyte differentiation, Col 2a1 and 
Aggrecan are expressed in proliferating chondrocytes and Col 10a1 is expressed in 
hypertrophic chondrocytes [140]. That the expression of these factors tends to be lower in 
the A2BAR KO might support the histology data, showing shorter growth plates at 2 
weeks of age (Fig. 11B). 
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Figure 11: Growth plates of WT and A2BAR KO mice. Femurs from 1, 2 and 4 week 
old male WT and A2BAR KO mice were sectioned and stained with safranin 0 (red: 
depicts cartilage) and fast green (blue/green: depicts bone). Growth plates are outlined in 
black. Growth plate height was measured in 4-7 sections per bone, at the mid-line 
(represented by dashed line), using SPOT imaging software and an average height was 
calculated for each bone. At 1 week of age, A2BAR KO mice tended to have similar 
growth plate height to WT (N=2). At 2 weeks of age, A2BAR KO mice had significantly 
shorter growth plate height (N=6, *p<0.05) while at 4 weeks of age the growth plate was 
significantly taller (N=3, *p<0.05). 4x magnification. Values represent averages +/-
standard deviation. 
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Figure 12: Chondrocyte mRNA expression in femurs of WT and A2BAR KO mice. 
RNA was isolated from whole femurs of WT and A2BAR KO male mice at 2 weeks of 
age. Sox9, Col 2al, Aggrecan and Col lOal expression was measured by qRT-PCR and 
expression was normalized to GAPDH mRNA expression. A2BAR KO mice tended to 
have lower expression of Sox9 (p=0.07), Col 2al (p=0.4), Aggrecan (p=O.l) and Col 
lOal (p=0.2). Values represent averages +1- standard deviation (N=4). 
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We also examined tibiae of younger mice (1-day old), when the bone is composed 
predominantly of cartilage. We chose to analyze the tibia, rather than the femur, as it is 
easier to remove consistently from the post-natal mice. WT and A2BAR KO mice 
showed no statistically significant differences in expression of Sox9, Aggrecan, and Col 
10a1 (Fig. 13A). At the protein level, there was no difference in Sox9 between the 
experimental groups, and there tended to be more Aggrecan in the A2BAR KO samples 
(Fig. 13B). Analysis of this data is limited as the possible increase in Aggrecan protein 
suggests more cartilage in the entire tibiae of A2BAR KO mice at one week of age, and is 
not restricted to the growth plate. A decrease in osteoblast differentiation and ossification 
in the A2BAR KO mice (as seen previously [54]) could account for the increased 
Aggrecan content. As to potential differences in WT and A2BAR KO samples at 2 weeks 
of age, a larger sample size is needed to reach firmer conclusions. 
Cranial bone development is somewhat impaired in A2BAR KO mice 
As we have previously found a role of the A2BAR in osteoblast differentiation 
[54], as well as some difference in growth plate dynamics in the A2BAR KO mice, we 
also carried out a gross analysis of the entire skeletons of 1-day old mice. Overall, there 
were no obvious changes in the spinal column, ribs, or forelimbs of the A2BAR KO 
mice, compared to WT (Fig. 14A). However, closer examination of the skulls showed 
impaired ossification of the parietal and interparietal bones of the A2BAR KO mice (Fig. 
14B,C). This observation is in line with our finding that A2BAR KO mice have impaired 
osteoblast differentiation but does not give information about chondrocyte 
differentiation/maturation, as the bones of the skull form independent of cartilage [1]. 
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This interesting observation related to decreased ossification of the parietal and 
interparietal bones in the A2BAR deleted mice will need further examination. 
Taken together, through analysis of the post-natal skeletal development of the 
A2BAR KO mice, we have found differences in the dynamics of the growth plate, which 
likely explain the differences previously seen in total femur length and trabeculae 
number. Additionally, we found impaired ossification of some bones of the skull, 
possibly due to diminished osteoblast differentiation in the A2BAR KO mouse . However, 
the skeletal effects of lack of the A2BAR are minor, without overt or pathological 
influence on the animal. 
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Figure 13: Chondrocyte expression and protein levels in 1-day old WT and A2BAR 
KO mice. A. RNA was isolated from whole tibiae of 1-day old WT and A2BAR KO 
mice. Sox9, Aggrecan, and Col lOal expression was measured by qRT-PCR and 
expression was normalized to GAPDH mRNA expression. Data shown represent 
averages +/- standard deviation (N= 4). A t test showed that the differences between the 
experimental groups were not statistically significant. B. Protein was extracted from the 
whole contra lateral tibiae and Sox9 and Aggrecan levels were measured by Western blot 
and normalized to ~-actin. Images were quantified with ImageJ software. There was no 
difference in Sox9 (p=0.9) and a trend towards increased Aggrecan levels (p=0.6) in the 
A2BAR KO mice relative to WT. Values represent averages +/- standard deviation 
(N=4). 
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Figure 14: Skeletons of 1 day-old WT and A2BAR KO mice. One day-old mice were 
removed of soft tissue and skeletons were stained with alizarin red (red: to depict bone) 
and alcian blue (blue: to depict cartilage). Lower limbs and skulls were removed prior to 
staining. A. Representative images of WT and A2BAR KO skeletons. No differences in 
the gross morphology of the spinal column, ribs or forelimbs of A2BAR KO mice were 
observed. B. Lateral view of the skulls of WT and A2BAR KO mice. The parietal and 
interparietal bones (depicted with arrows and outlined in black) may be smaller and less 
ossified in the A2BAR KO mice. C. Superior view of the skulls of WT and A2BAR KO 
mice . Again, parietal and interparietal bones (depicted with arrows and outlined in black) 
may be smaller and less ossified in the A2BAR KO mice. lx magnification. 
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Aim 3. The A2BAR affects the differentiation of mouse embryonic fibroblasts to 
chondrocytes 
Mouse embryonic fibroblasts (MEFs) from A2BAR KO mice have increased 
expression of Sox9 
In order to determine how lack of the A2BAR impacts chondrocyte differentiation 
in vitro, MEFs were isolated from WT and A2BAR KO mice at age e11.5. MEFs were 
differentiated to chondrocytes by plating in micro-mass cultures and treating with 100 
nM BMP2 as well as ascorbic acid and beta-glycerol phosphate (see methods). We found 
that prior to chondro-induction, A2BAR KO MEFs had increased expression of Sox9 
relative to WT (Fig. 15). 24 hours post-induction, Sox9 was increased in the WT and 
there was no difference between WT and A2BAR KO samples (Fig. 15). As Sox9 
expression increases with differentiation initiation, and then subsequently decreases 
[141], it is possible that Sox9 expression did increase with chondro-induction but then 
returned to baseline levels by 24 hours post-induction. It is also possible that Sox9 
expression in A2BAR KO samples was relatively high at chondro-induction and did not 
increase further. The consequence of these differences in Sox9 expression on 
chondrocyte terminal differentiation remain to be examined. 
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Figure 15: MEFs from A2BAR KO mice have increased expression of Sox9. Mouse 
embryonic fibroblasts (MEFs) were isolated from WT and A2BAR KO mice at age 
ell.5. MEFs were differentiated to chondrocytes by plating in micro-mass cultures and 
treating with chondro-induction reagents (see methods). RNA expression was measured 
by qRT -PCR and normalized to GAPDH mRNA expression. A2BAR KO MEFs had 
significantly higher expression of Sox9 at baseline, and there was no difference in 
expression 24 hours post-induction between WT and A2BAR KO samples. Values 
represent averages +1- standard deviation (N=3). *p<0.05 
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A2BAR activation inhibits chondrocyte differentiation in MEFs 
In addition to examining the effect of A2BAR KO , we also tested whether 
activation of the receptor with a specific agonist (BAY 60-6583; denoted as Bay) would 
modulate chondrocyte differentiation. We utilized commercially available WT C57Bl/6 
MEFs and induced differentiation as described above and in methods. Concurrent with 
chondro-induction, we treated cultures with 1 ~-tM Bay and found it to reduce Sox9 
expression, relative to treatment with vehicle, at 1 and 7 hours post-induction (Fig 16A). 
To test whether the effect of Bay is via an increase in cAMP, we also treated cultures 
with 1 ~-tM of the direct adenylyl cyclase activator Forskolin. Interestingly, there was no 
effect of Forskolin until 7 hours post-chondro-induction (Fig. 16A). This suggests the 
effect of A2BAR activation on Sox9 expression is due to additional signaling 
mechanisms or the kinetics of the cAMP signaling upon Bay treatment are needed for the 
early Sox9 decrease. Further experiments will elucidate the mechanism of Bay effect on 
Sox9 expression. 
To test whether the changes in Sox9 expression translate into changes in 
chondrocyte differentiation, we analyzed cultures 6 days post-chondro-induction. The 
expression of the cartilage proteins Col 2a1, Aggrecan and Col 10a1 increased 
significantly with chondro-induction, demonstrating that we are indeed inducing 
chondroctye differentiation in vitro (Fig. 16B). Treatment with Bay (1 uM) did not 
significantly alter mRNA expression of Col 2a1 or Aggrecan but Col 10a1 mRNA 
expression was significantly reduced with Bay treatment (Fig 16B). Proteoglycan 
accumulation, as evidenced by alcian blue staining was not different between vehicle and 
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Bay treated cultures (Fig. 16C). A larger sample size is needed to account for the amount 
of variability in these measures, however the Col lOal results suggest that A2BAR 
activation impairs chondrocyte differentiation. 
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Figure 16: A2BAR activation inhibits chondrocyte differentiation in MEFs. 
Commercially available WT MEFs were plated in micro-mass and treated with chondro-
induction reagents (see methods). Concurrent with chondro-induction, cells were treated 
with 1 !--1-M Bay, 1 !--1-M Forskolin (an adenylyl cyclase activator) or vehicle. A. RNA was 
isolated 1 and 7 hours post-chondro-induction and Sox9 expression was measured by 
qRT -PCR and normalized to GAPDH mRNA expression. Bay-treated cultures had 
significantly lower expression of Sox9 at 1 and 7 hours post-chondro-induction, 
compared to vehicle-treated ones (*p<0.05). The expression of Sox9 in Forskolin-treated 
cultures was significantly lower at 7 hours post-chondro-induction, compared to vehicle-
treated ones (*p<0.05). B. RNA was also collected 6 days post-chondro-induction. The 
expression of Col 2a1, Aggrecan and Col 10a1 was measured by qRT-PCR and 
normalized to GAPDH mRNA expression. For Aggrecan and Col 2a1, the differences 
between the experimental groups were not statistically significant (p>0.05) (N=5). There 
was a significant decrease in Col 10a1 mRNA expression in Bay treated samples 
(p<0.05) (N=5). C. Proteoglycan accumulation was detected by alcian blue staining of 
cultures 6 days post-chondro-induction. 1, 2 and 3 represent each biological replicate. 
Staining was quantified by measuring density using ImageJ software and values are 
graphed relative to vehicle treatment (N=3). Values represent averages +/- standard 
deviation. 
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A2BAR activation increases C/EBP-~ expression in MEFs during chondrogenesis 
Previously we have demonstrated that treatment of marrow-derived MSCs with 
Bay increases Runx2 expression [54]. Additionally, it has been shown that Runx2 inhibits 
specific stages of chondrocyte differentiation and maturation [142]. Here we found that in 
MEFs, Bay treatment had no effect on Runx2 expression at 1 and 7 hours post chondro-
induction (Fig. 17). Therefore, the inhibitory effect of A2BAR activation on chondrocyte 
differentiation is not dependent on increased Runx2 mRNA expression. This, of course 
does not rule out an effect of A2BAR agonism on Runx2 protein level or activation. 
CCAAT/enhancer binding protein-~ (C/EBP-~) is another factor known to regulate MSC 
differentiation [143]. Here we found that treatment with Bay significantly increased 
C/EBP-~ mRNA expression, relative to vehicle treatment, 1 hour post-induction (Fig. 
18). Forskolin also tended to increase C/EBP-~ expression, though this increase was not 
statistically significant (Fig 18). To test whether the inhibitory action of Bay on Sox9 
expression is due to its stimulatory effect on C/EBP-~ expression, we obtained C/EBP-~ 
KO MEFs and differentiated these cells to chondrocytes with and without Bay treatment 
(data not shown). In this single pilot experiment (carried out in triplicates), Sox9 mRNA 
expression was higher in C/EBP-~ KO at baseline (by 1 fold), relative to WT controls. 
Though Bay treatment decreased Sox9 expression in the WT cells by half a fold, it had 
no effect in the C/EBP-~ KO cells. Additionally, C/EBP-~ KO cells failed to differentiate 
to chondrocytes, as evidenced by alcian blue staining. In the same experiment, WT MEFs 
upregulated Sox9 mRNA expression upon chondro-induction and were positive for alcian 
blue staining, indicating chondrocyte differentiation. Further experiments are needed to 
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test the significance of increased C/EBP-~ expression on chondrocyte differentiation and 
whether this is a mechanism of Bay's inhibitory action. 
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Figure 17: Runx2 expression during chondrocyte differentiation with Bay 
treatment. Commercially available WT MEFs were plated in micro-mass and treated 
with chondro-inductive reagents (see methods). Concurrent with·chondro-induction, cells 
were treated with 1 ~-tM Bay, 1 ~-tM Forskolin or vehicle . RNA was collected 1 and 7 
hours post-chondro-induction and Runx2 expression was measured by qRT -PCR and 
normalized to GAPDH mRNA expression. Treatment with Bay or Forskolin had no 
effect on Runx2 expression at these time points. Values represent averages +1- standard 
deviation (N=3); p>0.05 (comparing each treatment to baseline). 
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Figure 18: C/EBP-~ expression during chondrocyte differentiation with Bay 
treatment. Commercially available WT MEFs were plated in micro-mass and treated 
with chondro-inductive reagents (see methods). Concurrent with chondro-induction, cells 
were treated with 1 f-1-M Bay, 1 f-1-M Forskolin or vehicle. RNA was collected 1 hour post-
chondro-induction and C/EBP-f3 expression was measured by qRT -PCR and normalized 
to GAPDH mRNA expression. Treatment with Bay significantly increased C/EBP-f3 
expression, relative to vehicle treatment (*p<0.05). Forskolin also tended to increase 
C/EBP-f3 expression (p=0.05). Values represent averages +1- standard deviation (N=3). 
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CHAPTER IV: DISCUSSION 
Aim 1: The role of the A2BAR in bone repair and in the differentiation of bone 
marrow mesenchymal stem cells to osteoblasts 
MSC differentiation to osteoblasts plays a necessary role in the development and 
postnatal growth and homeostasis (reviewed in [144]) as well as skeletal tissue repair 
after injuries such as fracture [145]. Though the origin of the osteoblasts involved in 
fracture healing has not been demonstrated unequivocally, experimental evidence is 
accumulating to support the hypothesis that some of the MSCs that contribute to repair 
are harbored in the bone perivasculature [146], and upon receiving a signal (one of which 
being stromal derived factor-1 (SDF-1) [145]) travel, through the marrow capillaries 
[144] or neovasculature [147], to the site of injury or stress. 
Here, we used genetic ablation to study the role of the A2BAR in bone 
homeostasis and repair in vivo, and examined the potential mechanisms that were 
involved using in vitro studies of MSC differentiation. We present direct evidence that 
the A2BAR plays a role in osteoblast differentiation. We have also demonstrated that 
activation of this receptor with a pharmacological agonist can enhance osteoblast 
differentiation. This effect is likely due to the modulation of levels of the transcription 
factors essential for osteoblast differentiation, Runx2 and Osterix. This claim is supported 
by previous data demonstrating increased osteoblast differentiation with the 
overexpression of either Runx2 [148] or Osterix [149]. Of note, however, the effect of 
A2BAR activation on osteoblast differentiation is much milder than the effect of this 
receptor ablation. This raises the possibility that the receptor influences these processes 
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independent of its activation, e.g., via its potential association with other regulatory 
pathways or proteins yet to be explored, which would be lost upon receptor deletion . 
Genetic deletion of the receptor impacted bone fracture callus development and likely 
delayed normal fracture physiology. It had long been accepted that the low affinity 
A2BAR plays an important role in tissue injury , as extracellular adenosine levels increase 
after various types of stress/ injury and in various organs (reviewed in [76]). Many 
studies of bone have examined extracellular concentrations of ATP and ADP, and the 
expression of their receptors, P2X and P2Y [150]. Extracellular ATP concentrations 
increase after bone injury and, when exposed to hypoxic conditions, osteoblasts secrete 
ATP in the high nM to f!M range [151]. This ATP is catabolized by ectonucleotidases, 
also expressed on osteoblasts [133] . Of note, it was recently demonstrated that genetic 
ablation of the ectonucleotidase CD73, an enzyme upstream of A2BAR signaling (by 
converting AMP to adenosine), results in osteopenia and decreased osteoblast 
differentiation [152]. Although we too demonstrate diminished osteoblast differentiation 
ex vivo in A2BAR KO samples, it is likely that this explains only part of the reduced 
bone density in the fracture callus. Fracture healing is complex, and the A2BAR may 
have a role in other stages of the process, such as the inflammatory response. This 
possibility should be considered in the context of fracture healing since inflammatory 
cytokines, particularly TNF-a, have been shown to downregulate the expression of the 
osteoblast differentiation genes Runx2 [90] and Osterix [95]. Also, A2BAR KO mice 
tend to display a mild increase in the levels of inflammatory cytokines at baseline, and 
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more so post-vascular injury, partially attributed to cAMP modulation of macrophage 
expression of cytokines [65, 104]. 
Our current study also points to a potential role for A2BAR signaling in the 
regulation of callus cartilage density post-injury. Others have documented A2BAR 
expression in chondrocytes [80], the source of cartilage, as well as the role of cAMP 
signaling in preventing [153] as well as promoting [71] their differentiation. This 
differential effect of cAMP might be attributed to how chondrocyte differentiation is 
being measured, i.e. differentiation versus maturation of chondrocytes. In Aim 2 of this 
thesis research we initiated studies to explore the potential effect of A2BAR expression 
on the development of embryonic and adult chondrocytes. 
Finally, our study is the first to describe a role for the A2BAR in bone development 
and homeostasis. Intriguingly, the bone phenotype of the A2BAR KO mouse produces a 
similar but milder phenotype comparable to what is observed for the PTH receptor (PPR) 
KO mouse [42], suggesting a possible synergy between the two receptors during bone 
development. We found that genetic ablation of the A2BAR causes a significant decrease 
in the early ( 4-week old) development of trabecular bone however, the differences 
normalize by 8 weeks of age. The genesis of trabecluar bone depends on the 
differentiation of cells of multiple lineages, including osteoblasts and chondrocytes, and 
the coordinated action of these cells [154]. Impairment in osteoblast differentiation in the 
A2BAR KO mouse may impact the development of the perichondrium and, at least 
partially, explain the reduced trabecular bone formation in the A2BAR KO. The lack of 
difference in trabecular bone in older mice (8 and 15-weeks old) may be due to the 
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diminished contribution of stem cell differentiation towards trabecular bone homeostasis 
at these ages, since in earlier periods of growth many more cells contribute towards 
juvenile tissue development. In addition, our finding that the A2BAR KO femurs are 
shorter, with a trend towards increased height of the hypertrophic zone and entire growth 
plate, are consistent with the effects of removing the perichondrium during endochondral 
bone development [154]. Therefore, A2BAR deletion may be delaying periosteal 
development with subsequent consequences on endochondral ossification and growth 
plate regulation. Future investigation of skeletal development in the A2BAR KO mouse 
could test these hypotheses. 
Taken together, our study identified the A2BAR as an important regulator of 
osteoblast transcription factor expression and of MSC differentiation to osteoblasts, as 
well as a regulator of bone homeostasis and fracture physiology. 
Aim 2: The impact of A2BAR deletion on skeletal development 
We analyzed femurs of adult WT and A2BAR KO mice at baseline (i.e. in the 
absence of stress or injury) and found A2BAR KO mice to have slightly shorter femurs 
and a decrease in the number of trabeculae in the distal metaphysis. Additionally , we 
found that these differences in the A2BAR KO mice diminished with age. For this aim of 
research, we chose to expand the investigation of the baseline bone phenotype of the 
A2BAR KO mice by studying the skeleton, particularly the growth plate, in growing 
mice. Longitudinal growth of the femur is dependent on specific aspects of the growth 
plate, specifically chondrocyte proliferation, extracellular matrix secretion and 
hypertrophy [155]. Additionally, the formation of trabecular bone is the result of 
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mineralization of the vertical cartilage septa, remaining after chondrocyte hypertrophy 
and physiological death, by osteoblasts [155]. Therefore, we hypothesized that A2BAR 
KO mice would possess morphological differences in the growth plate, compared WT 
mice. 
The development and maturation of the growth plate is a dynamic process. In WT 
mice, the height of the growth plate increases between 1 and 2 weeks and then decreases 
between 2 and 4 weeks. We found that at 2 weeks of age A2BAR KO mice have a 
significantly shorter growth plate. However at 4 weeks of age the height of the growth 
plate of A2BAR KO mice is significantly taller. Histological measurement of the growth 
plate is the historical method for analyzing bone growth. New technology, using micro-
CT analysis of bones stained with a cartilage specific dye, will allow us to measure the 
growth plate more precisely and should be sensitive enough to detect small changes in 
growth plate morphology. 
In addition to histology, we also analyzed the mRNA expression of chondrocyte 
genes, as a decrease in the number of chondrocytes may result in a decrease in the 
amount of mRNA. At 2 weeks of age there was a tendency towards decreased mRNA 
expression of Sox9, Col 2a1, Aggrecan and Col 10a1, however the variability between 
mice was large and the values were not statistically significant. The mRNA expression of 
Sox9, Aggrecan and Col 10a1 at 1 week of age also tended to be lower in the A2BAR 
KO mice, compared to WT. Conversely, the protein level of Aggrecan tended to be 
higher in the A2BAR KO at 1 week of age. Therefore , mRNA expression does not 
necessarily correlate with protein level, and whether there is a difference between WT 
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and KO growth plates at 1 week of age remains to be determined. Biochemical analysis 
of total glycosaminoglycan content of WT and A2BAR KO bones will be a better 
indicator of total cartilage, and will be used in the future to validate histology and micro-
cr data. 
Based on this data we can conclude that the dynamics of the growth plate are 
different in the A2BAR KO mice, compared to WT mice. This may be attributed to a 
delay in the initiation of endochondral ossification in the A2BAR KO, thereby shifting 
the curve of growth plate expansion and diminution. In essence, the growth plate of the 
A2BAR KO may be "lagging behind" the normal progression of the WT growth plate. 
Analysis of the initiation of chondrocyte differentiation, the formation of the cartilage 
analgen and of the initiation of the primary ossification center in embryos are needed to 
test this supposition. 
Often, growth plate alterations are due to differences in the proliferation or 
maturation (hypertrophy and cell death) of chondrocytes. Typically, these differences 
persist during bone growth and are reflected in the relative heights of the zones of the 
growth plate (e.g. [156]). However, we found the growth plate of the A2BAR KO mice to 
be shorter at 2 weeks of age and taller at 4 weeks of age, compared to WT, with no 
differences in the ratios of proliferating or hypertrophic zones. This suggests that if there 
are differences in chondrocyte proliferation or maturation, they are not persistent. 
Additionally, any effect on one process would have to be compensated for by a similar 
action on the other process , so that the relative ratios remain equal. An additional, and 
more likely explanation for the observed growth plate aberrations in the A2BAR KO is a 
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delay in the initiation of growth plate formation. This would result in a lag ·in normal 
growth plate changes, relative to the WT. Further analysis of the formation of the growth 
plate during embryogenesis and of proliferation and cell death , via immunohistochemical 
staining, are needed to understand the mechanisms involved. 
Aim 3: The A2BAR affects the differentiation of mouse embryonic fibroblasts to 
chondrocytes 
Analysis of the fracture callus of A2BAR KO mice (Aim 1; [54]) demonstrated an 
increased volume of cartilage at 14 days post-fracture, relative to WT. This caused us to 
question whether the A2BAR is involved in the regulation of chondrocyte differentiation. 
To this end, we chose to study chondrocyte differentiation in vitro, utilizing mouse 
embryonic fibroblasts (MEFs). Though these cells are a heterogeneous mixture of 
embryonic cells, they have been shown to differentiate in culture similarly to MSCs 
[132]. Initially, we found that A2BAR KO MEFs have a higher baseline expression of 
the chondrocyte differentiation transcription factor Sox9, relative to WT. Additionally, 
this expression did not increase after 24 hours post-chondrocyte-induction, as it did in the 
WT cells . These results are difficult to interpret as the MEFs isolated from A2BAR KO 
embryos are likely different than those isolated from WT mice in numerous ways, and 
therefore may respond differently to culturing and differentiation conditions. A more 
powerful experiment will be to knockdown A2BAR expression in WT MEFs prior to 
chondro-induction. These results could reveal a more direct role of the A2BAR on 
chondrocyte differentiation. 
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In addition to testing the effect of absence of the A2BAR on chondrocyte 
differentiation, we also examined whether receptor activation would effect chondrocyte 
differentiation. For these experiments, we treated cultures with the specific A2BAR 
agonist BAY 60-6583 (Bay). We found that A2BAR activation caused a decrease in the 
expression of Sox9 and tended to decrease chondrocyte differentiation, though a larger 
sample size is needed. We explored a number of different mechanisms for this decreased 
expression. We have previously shown that A2BAR activation causes the upregulation of 
Runx2 mRNA expression in bone marrow-derived MSCs [54]. As Runx2 is thought to 
promote osteoblasts versus chondrocyte differentiation of MSCs [9], we tested whether 
A2BAR activation is causing an increase in Runx2 mRNA, which is subsequently 
downregulating Sox9 mRNA expression. We found that in these cultures, A2BAR 
activation had no effect on Runx2 mRNA levels at time points when Sox9 is already 
decreased . Therefore, it does not appear that Bay treatment decreases Sox9 mRNA 
expression through increases in Runx2 transcription. However it is still possible that 
Runx2 is being regulated at the protein or activation level. 
Another mechanism we explored is inhibition of chondrocyte differentiation 
through increased C/EBPj3 expression. C/EBPj3 is a transcription factor well established 
to be important for adipocyte differentiation, but also involved in various aspects of cell 
physiology, including apoptosis and metabolism, as well as differentiation to various 
lineages , including keratinocytes and mammary epithelial cells (reviewed in [157]). We 
found that A2BAR activation caused an increase in C/EBPj3 mRNA expression 1 hour 
after chondro-induction. We have furthered this line of experimentation by treating 
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C/EBPB KO MEFs with the A2BAR specific agonist Bay, during chondro-induction. We 
hypothesized that the inhibitory action of Bay would be diminished or abolished in the 
absence of C/EBPB, if this factor is responsible for mediating the effect of Bay on Sox9. 
A single pilot study demonstrated that Bay treatment did not reduce Sox9 mRNA levels 
in C/EBPB cells. However, C/EBPB KO cultures had elevated Sox9 mRNA expression at 
baseline, relative to WT, and therefore, Sox9 expression may have been insensitive to the 
effect of Bay. In future experiments we will use siRNA to knockdown C/EBPB in WT 
MEFs, prior to Bay treatment and chondro-induction. 
Thesis summary and future directions 
In summary, we have established a role for the A2BAR in the differentiation of 
osteoblasts and we were the first to utilize cells from A2BAR KO mice for osteoblast 
differentiation. In addition, ours is the first to demonstrate the importance of the A2BAR 
KO in bone repair in vivo. Additionally, these data support involvement Qf the A2BAR in 
the regulation of some aspects of skeletal development, such as the growth plate and 
some bones of the skull. Finally, our data point to theA2BAR as regulator of chondrocyte 
differentiation. These findings have been summarized in Schematic 4. 
The A2BAR has been thought of as important modulator of inflammatory 
processes during physiological stress or injury, when extracellular adenosine levels are 
elevated [158]. Our research demonstrates a novel role of the A2BAR in MSC 
differentiation to osteoblasts, likely resulting in less total bone during normal and injured 
physiological circumstances, and possibly implications for the differentiation to the 
chondrocyte lineage as well. Currently, there is no evidence that extracellular adenosine 
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reaches concentrations necessary for A2BAR activation during development. This 
conjures the possibility that MSCs are secreting a sufficient amount of adenosine, or 
ATP, to activate A2BAR in a paracrine manner. Interestingly, Pannexin 3 is a 
hemichannel that has been shown to be responsible for A TP release from cells and to 
promote chondrocyte differentiation [153] and osteoblast differentiation [159]. Pannexin 
3, in combination with extracellular nucleotidases, is one possible mechanism for 
increased extracellular adenosine during differentiation. The relationship between 
Pannexin 3 and A2BAR signaling in MSC differentiation could be an interesting area of 
future research. 
Another possible explanation for A2BAR activation during development is that 
the receptor has functions that are ligand independent, possibly through interactions with 
unknown protein or receptors. LRP5/6 are co-receptors involved in canonical Wnt 
signaling by interacting with Frizzled, a G-protein coupled receptor (GPCR) [27]. Recent 
studies have also shown LRP5/6 to be essential to signaling of other GPCRs including the 
PTH receptor [160]. Of particular interest, cAMP levels failed to increase in response to 
adenosine in bronchial smooth muscle cells with LRP6 and LRP5/6 knocked down by 
siRNA [160]. The particular adenosine receptor was not identified in this study and 
further experiments with specific adenosine receptor agonists should be performed. 
Another recent publication has demonstrated binding of ~-catenin to the C-terminal 
region of the PTH receptor, which modulates PTH signaling and cAMP levels [161]. 
Initial analysis of the amino acid sequence of the C-terminal region of the mouse A2BAR 
(residues 292-332) showed zero identity with the C-terminal region of the mouse PTH 
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receptor 1 that was found to interact with 13-catenin (residues 583-591). If the A2BAR is 
found to interact with Wnt signaling, either directly or indirectly, one might expect lack 
of the A2BAR to modulate Wnt-dependent cell differentiation. Future experiments are 
needed to explore these possibilities. 
Finally, A2BAR KO mice have a mild inflammatory phenotype [104], and 
inflammation, in particular TNFa, impairs the differentiation of osteoblasts and 
chondrocytes [88, 162]. Our lab has identified p105, an inhibitor of NFKB, as being 
stabilized by binding to the A2BAR and subsequently inhibiting NFKB signaling by 
sequestering in the cytoplasm [106]. Hence, in A2BAR KO cells, NFKB is more active. 
This may be inhibiting osteoblast and chondrocyte differentiation and thereby altering the 
development of the skeleton and the repair of the bone after fracture. Our in vitro data 
showing A2BAR activation to increase osteoblast differentiation and decrease 
chondrocyte differentiation might seem inconsistent with this explanation, as it was 
demonstrated that agonism of the receptor did not impact the interaction with p105 [106] 
and, there is not indication that A2BAR activation and signaling has an inhibitory effect 
on NFKB activation. 
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Schematic 4: Summary of findings regarding the activation of the A2BAR during 
osteoblast and chondrocyte differentiation, with ultimate effects on bone formation. 
Unknown mechanisms for future experiments are depicted in blue and represented by (X) 
and unknown effects of the A2BAR, also yet to be investigated, are depicted in blue and 
represented by (?).Lines depicted in green illustrate processes identified during this PhD 
thesis research. 
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f---- A2BAR KO 
We have found that A2BAR activation in MEFs, during chondro-induction, leads 
to an early upregulation of C/EBP~ mRNA expression. The majority of the data on 
C/EBP~ role in MSC differentiation is in the adipocyte lineage, though there are some 
studies in osteoblasts and chondrocytes. C/EBP~ KO mice exhibit a dwarfed phenotype 
at age e16.5 [163, 164]. Interestingly, after birth the skeletons of the C/EBP~ KO mice 
begin to "catch up" to their WT littermates and there is no difference by 1 week of age 
[163]. This may be explained by compensation by other C/EBP family members [163]. 
Utilizing primary cells from the C/EBP~ KO mice, as well as overexpression of C/EBP~ 
in an MSC cell line, C/EBP~ was found to transactivate p57Kip2 , thereby halting 
proliferation and promoting cell hypertrophy, in differentiated chondrocytes [163]. The 
effect of C/EBP~ during the initial differentiation of chondrocytes was not reported in 
this study. We hypothesize, and are further testing, that the decrease in Sox9 mRNA 
expression with A2BAR activation is a result of the upregulation of C/EBP~. A direct 
effect of C/EBP~ on Sox9 expression has not been described. Analysis of the mouse 
Sox9 gene promoter revealed two putative C/EBP~ binding sites at -20Kb 
(AGGTTGCGACAGTC and AGATTGAGAAACGT) and C/EBPa binding sites at -
20Kb (AGGTTGCGACAGTC) and +2Kb (AGGTGCACTCCCC) from the 
transcriptional start site. A CHIP assay of the Sox9 gene promoter during chondrocyte 
differentiation, in the presence of A2BAR activation, would be informative in regard to 
negative regulators of the Sox9 promoter. Microarray analyses of C/EBP~ KO 
endometrial stromal cells [165] and mammary epithelial cells [166] did not reveal any 
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changes in Sox9 mRNA expression, however Sox9 is likely not expressed significantly in 
these cell types. A microarray analysis of C3H10Tl/2 cells, an MSC cell line, 
overexpressing C/EBP~ did reveal a 1.3 fold decrease in Sox9 expression, supporting the 
notion that C/EBP~ is a negative regulator of Sox9 [163]. Whether this effect is direct or 
indirect remains to be determined. Of note, there was no change in A2BAR expression in 
these C/EBP~ overexpressing cells, according to the microarray data [163]. However, 
because these cells were analyzed 1 week into chondrocyte differentiation, based on our 
own observations, we would expect A2BAR expression to already be downregulated. 
Taken together, an additional line of future experiment could focus on identifying a 
potential connection between A2BAR signaling, C/EBP~ expression and a consequential 
control of Sox9 and chondrocyte differentiation. 
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